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ABSTRACT  
Alzheimer’s disease (AD), like most neurodegenerative disorders, is 
characterized by accumulation of misfolded and aggregated proteins, indicating that the 
protein quality control machinery is compromised.  Enhancing the activity of molecular 
chaperones such as the ‘heat shock’ proteins (Hsp’s) that re-fold or signal degradation 
of damaged proteins may help remove protein oligomers/aggregates and prevent cell 
death.  The goal of our studies was to characterize a novel, non-toxic Hsp90 modulator, 
KU-32, which protects primary cortical neurons against Aβ1-42, a toxic peptide found in 
AD brain.  Pharmacokinetic studies indicated that KU-32 is blood brain barrier 
permeable and orally bioavailable.  Using two AD mouse models, JNPL3 and rTg4510, 
which both contain the P301L Tau mutation and develop aberrant Tau tangles as well 
as cognitive impairments, we assessed KU-32 treatment in vivo.  The JNPL3 mice were 
treated with 20 mg/kg of KU-32 or with 12.5% Captisol® (vehicle) five times a week for 
six months.  Immunohistochemical studies indicated significant decreases of 
hyperphosphorylated Tau in the cortical region.  The rTg4510 mice were treated with 60 
mg/kg of KU-32 or with vehicle (5% Captisol®) twice a week for 10 weeks.  
Immunofluorescent analyses demonstrated significant protection against dendritic 
pathology and neuronal death in KU-32-treated vs vehicle-treated rTg4510 mice. 
Further studies were conducted to examine the potential mechanisms of drug action.  
We hypothesized that KU-32 activated the heat shock response leading to an increase 
in molecular chaperones involved in protein quality control such as Hsp70.  Our data 
suggest that KU-32 is not acting through this mechanism, and further studies are 
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needed to elucidate the mechanism.  Overall, our in vivo results suggest that the novel 
Hsp90 modulator, KU-32, may have therapeutic potential for treatment of AD. 
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CHAPTER ONE: Novel Modulators of Hsp90 as a Therapeutic 
Approach for Alzheimer’s Disease 
 
1. PATHOLOGICAL CHARACTERISTICS OF NEURODEGENERATIVE DISEASES 
 Most neurodegenerative disorders are characterized by the accumulation of 
aggregated proteins.  These aberrant proteins manifest in areas of the brain that 
regulate cognitive and motor functions.  The deposition of these ‘misfolded’ proteins is 
cytotoxic, causing improper cell function and ultimately death.  Some of these diseases 
include: Huntington’s disease (HD) with mutant huntingtin; Parkinson’s disease (PD) 
with accumulated α-synuclein; amyotropic lateral sclerosis (ALS) containing mutant 
superoxide dismutase-1 (SOD1) and TAR DNA-binding protein-43 (TDP-43) deposits; 
and spinal and bulbar muscular atrophy (SBMA) with mutant androgen receptor 
aggregates (Muchowski and Wacker, 2005).   
The most common age-related dementia, Alzheimer’s disease (AD), is 
characterized by the development of lesions made of two misfolded protein aggregates; 
senile plaques (SPs) comprised of the β-amyloid peptide and neurofibrillary tangles 
(NFTs) made up of hyperphosphorylated Tau, a microtubule stabilizing protein.  These 
lesions are deposited in cortical and limbic regions of the brain leading to devastating 
cognitive and memory impairments.  Although AD has been studied extensively, 
promising therapeutic candidates that slow progression of the disease and ameliorate 
these toxic aggregates are proving difficult to develop. 
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Prevalence of Alzheimer’s Disease (AD) 
Presently, AD is the sixth leading cause of death in the United States with an 
estimated 5.4 million individuals living with the disease in 2012 (Alzheimer's, 2012).  
One in eight people over the age of 65 have AD (5.2 million) (Hebert et al., 2003).  As 
the baby boomer generation ages, the proportion of individuals over 65 with AD is 
expected to rapidly increase.  In this particular population, more women than men have 
AD.  Approximately, 3.4 of the 5.2 million people over age 65 with AD are women while 
1.8 million are men (Seshandri et al., 1997).  This difference is attributed to the fact that 
women live longer than men (Hebert et al., 2001).  However, as individuals age the 
likelihood of developing AD is much greater with an estimated 46% of people over 85 
living with AD (Hebert et al., 2003).   
The development of AD in an aging population places a tremendous burden on 
caregivers.  It is estimated that 80% of caregivers are unpaid, and provide care in their 
homes, at the expense of their careers, income, and emotional state (Institutes of 
Medicine, 2008).  In 2011, the unpaid hours provided by an AD caregiver was estimated 
at $17.4 billion.  Healthcare costs attributed to AD are expected to be about $200 billion 
in 2012 (Alzheimer’s Association, 2012). 
Sadly, the diagnosis of AD is difficult, though new strategies are becoming 
available.  Most individuals are diagnosed when symptoms develop, which occurs 
relatively late in disease progression.  Many of the earliest, sometimes neglected 
symptoms include: difficulty remembering names, places, or recent events.  Individuals 
with AD become apathetic or depressed.  As the disease advances people begin to 
have motor problems such as difficulty swallowing, walking, or speaking.  Prominent 
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behavioral changes are accompanied by disorientation, confusion, and impaired 
judgment (Alzheimer’s Association, 2012).  AD progression is insidious, and the disease 
ultimately leads to death.  
Although AD is difficult to detect, there have been significant strides in 
developing better diagnostic tools.  First, is the development of clinical diagnosis criteria 
including the DSM IV Clinical Criteria and the NINDS ADRDA Criteria.  Individuals with 
cognitive decline are given various memory and physiological tests.  The results of 
these tests determine which level of cognitive decline the patient is currently exhibiting 
(Psychiatric Association, 2000, Dubois et al., 2007). The physiological tests given 
include PET scans to measure neuronal metabolism (Mosconi et al., 2008), MRI scans 
to determine brain atrophy (Jack et al., 2000), Pittsburgh Compound-B (PIB) which 
labels amyloid aggregates in the brain (Mathis et al., 2008), and cerebral spinal fluid 
(CSF) measurements of phosphorylated Tau and Aβ peptides (Andreasen et al., 2001, 
Reimenschneider et al., 2001).  These tests help positively diagnose individuals with 
mild to moderate AD as well as distinguish AD from other misfolded protein diseases; 
however there are still many patients with early cognitive impairments that are 
overlooked (Gabriela-Fita et al., 2001).  Even though these breakthroughs in the 
diagnosis of AD have improved overall detection in humans, a more accurate measure 
is still desired.  
 
Pathological Characteristics of AD 
The amyloid plaques and neurofibrillary tangles were first described in 1907 by 
the German neuropathologist Alois Alzheimer.   He discovered the lesions after 
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performing silver staining on brain tissue from his patient, Auguste Deter, who died at 
age 51 with severe memory and cognitive dysfunctions.  Before this discovery by 
Alzheimer, doctors and non-scientific members of the community thought dementia was 
an inherent part of aging.  The implications of this discovery were not appreciated until 
nearly 100 years later.  This concept that there was a neuropathological phenotype 
associated with dementia, led to an explosion of scientific research dedicated to 
determining the origins of the lesions and their characteristics.  This disease was named 
for the neuropathologist who discovered it, i.e. Alzheimer (Selkoe, 2001).   
In 1984, Glenner and Wong isolated the amyloid peptide from the plaques in the 
brains of patients with Alzheimer-like dementia.  The peptide was sequenced and 
further studies determined that this 40 to 42 amino acid peptide was the main 
component of SPs (Masters et al., 1985, Miller et al., 1993).  It was not until 1986 that 
the protein in NFTs was characterized and revealed as the microtubule associated 
protein Tau (Grundke-Iqbal et al., 1986a).  Since the discovery of the composition of the 
pathological proteins associated with AD, there has been a plethora of scientific 
research undertaken to elucidate the causes of the disease in hopes of developing 
interventions to stop disease progress.  Unfortunately, two problems still remain; the 
complexity of AD diagnosis, and the lack of promising disease-reversal therapeutics.  
 
Genetic Causes and Risk Factors for AD 
Many risk factors are associated with AD although the exact cause of the 
majority of cases remains unknown.  AD presents itself in three different forms: early 
onset FAD, late-onset familial Alzheimer’s dementia, familial AD (FAD), and a sporadic 
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late-onset, nonhereditary form. Sporadic, late onset AD is the most common, and 
represents about 95% of AD patients (Alzheimer’s Association, 2012).  
Early onset FAD is associated with mutations in three different genes: amyloid 
precursor protein (APP) on chromosome 21, Presenilin 1 (PSEN1) on chromosome 14, 
and Presenilin 2 (PSEN2) on chromosome 1.  PSEN1 mutations are the predominant 
genetic determinants of FAD; however, taken together the PSEN1 and PSEN2 
mutations are responsible for about 90% of FAD mutations (Ho and Shen, 2011).  Late 
onset, FAD is linked with apolipoprotein 4 (APOE4), and represents susceptibility more 
than a genetic determinant.  Sporadic AD has multiple environmental causes with aging 
being the greatest risk factor.   In the next set of subsections, the different forms of AD 
will be discussed in greater detail.  
 
Early onset FAD 
Amyloid precursor protein (APP) is a transmembrane protein and, although its 
role in AD has been well characterized, the normal biological function of this protein is 
not well understood. A group of enzymes called secretases are responsible for 
processing APP. The enzymes within this group are designated as α, β, and γ-
secretases. 
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‘with permission’ Selkoe, DJ. (2001).  Alzheimer’s Disease: Genes, Proteins, and Therapy. Physiological Reviews, 81(2), 741-766 
Figure 1.1: Proteolytic processing of APP. 
Amyloid precursor protein (APP) exists as an integral membrane protein in neurons.  
Full length APP is drawn at the top of the schematic, which consists of 770 amino acids.  
Three enzymes cleave APP: α-,β-, and γ-secretases.  The second APP illustration in 
the schematic demonstrates subsequent cleavage by α- and γ-secretase, which 
produces sAPPα and a soluble fragment termed p3.  This pathway is called the non-
amyloidogenic pathway.  The third APP representation shows cleavage by β- and γ-
secretase, which generates sAPPβ and a 40 to 42 amino acid peptide called Aβ.  This 
pathway is referred to as the amyloidogenic pathway as it produces the toxic Aβ 
peptides that aggregate into senile plaques (SPs). 
 
As demonstrated in Figure 1.1, proteolytic processing of APP by the secretases 
can occur through two different pathways, the non-amyloidogenic or the amyloidogenic 
pathway.  The non-amyloidogenic pathway begins with α-secretase.  This enzyme cuts 
within the Aβ sequence, thereby preventing the formation of toxic Aβ peptides.   
Cleavage by α-secretase produces a soluble form of APP (sAPPα) that can be released 
and a C-terminal fragment (C83) that retains association with the membrane.  This C-
terminal fragment is further processed by γ-secretase that generates a soluble fragment 
called p3 (Haass et al., 1992, Haass et al., 1993).  
tors (KPI), indicating one potential function of these
longer APP isoforms. Indeed, the KPI-containing forms of
APP found in human platelets serve as inhibitors of factor
XIa, which is a serine protease in the coagulation cascade
(158). APP is highly conserved in evolution and expressed
in all mammals in which it has been sought. A partial
homolog of APP is found in Drosophila (referred to as
APPL) (130). Indeed, APP is a member of a larger gene
family, the amyloid precursor-like proteins (APLPs) (157,
182), which have substantial homology, both within the
l rge ectodomain a d particularly within the cytoplasmic
tail, but are largely divergent in the A! region.
B. Trafficking and Proteolytic Processing of APP
APP is a single transmembrane polypeptide that is
cotranslationally translocated into the endoplasmic retic-
ulum via its signal peptide and then posttranslationally
modified (“matured”) through the secretory pathway. Its
acquisition of N- and O-linked sugars occurs rapidly after
biosynthesis, and its half-life is relatively brief (!45–60
min in most cell types tested) (183). Both during and after
the trafficking of APP through the secretory pathway, it
can undergo a variety of proteolytic cleavages to release
secreted derivatives into vesicle lumens and the extracel-
lular space (Fig. 1). The first proteolytic cleavage identi-
fied, that made by an activity designated "-secretase,
occurs 12 amino acids NH2-terminal to the single trans-
membrane domain of APP (28, 156). This processing re-
sults in the release of the large soluble ectodomain frag-
ment ("-APPs) into the lumen/extracellular space and
retention of an 83-residue COOH-terminal fragment (CTF)
in the membrane. Alternatively, some APP molecules not
subjected to "-secretase cleavage can be cleaved by an
activity designated !-secretase, which principally cuts 16
residues NH2-terminal to the "-cleavage site, generating a
FIG. 1. Schematic diagrams of the !-amyloid pr cursor prot in (APP) and its principal metabolic derivatives. Top
diagram depicts the largest of the known APP alternate splice forms, comprising 770 amino acids. Regions of interest are
indicated at their correct relative positions. A 17-residue signal peptide occurs at the NH2 terminus (box with vertical
lines). Two alternatively spliced exons of 56 and 19 amino acids are inserted at residue 289; the first contains a serine
protease inhibitor domain of the Kunitz type (KPI). A single membrane-spanning domain (TM) at amino acids 700–723
is indicated by the vertical dotted lines. The amyloid ß-protein (A!) fragment includes 28 residues just outside the
membrane plus the first 12–14 residues of the transmembrane domain. In the middle diagram, the arrow indicates the
site (after residue 687; same site as the white dot in the A! region of APP in the upper diagram) of a constitutive
proteolytic cleavage made by protease(s) designated "-secretase that enables secretion of the large, soluble ectodomain
of APP (APPs-") into the medium and retention of the 83-residue COOH-terminal fragment in the membrane. The C83
fragment can undergo cleavage by a protease(s) called #-secretase at residue 711 or residue 713 to release the p3
peptides. The bottom diagram depicts the alternative proteolytic cleavage after residue 671 by a protease(s) called
!-secretase that results in the secretion of the slightly truncated APPs-! molecule and the retention of a 99-residue
COOH-terminal fragment. The C99 fragment can also undergo cleavage by #-secretase to release the A! peptides.
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The amyloidogenic pathway involves APP cleavage by both β- and γ-secretases.  
First, β-secretase cuts APP outside the Aβ sequence.  Proteolysis results in a soluble 
fragment called sAPPβ, and a C-terminal fragment (C99) that stays within the 
membrane (Marlow et al., 2003).   The C-terminal fragment produced by β cleavage, is 
then processed by the enzyme γ-secretase.   When γ-secretase cleavage of C99 
occurs, the product is toxic Aβ peptides ranging from 39 to 43 amino acids in sequence 
(Yu et al., 2001).  The most abundant, less toxic form is Aβ1-40, which represents about 
80-90% of the amyloid-β peptides, and the longer form Aβ1-42 is only about 10% of the 
secreted peptides.  However, the longer Aβ1-42 variant is the main component of senile 
plaques associated with AD (Jarrett et al., 1993).  Mutations within the APP determine 
whether the amyloidogenic or non-amyloidogenic pathway is followed.  For example, 
the APP Swedish mutation stimulates more β-secretase processing of APP leading to 
greater production of toxic Aβ peptides (Sinha et al., 1999).      
 As mentioned previously, early onset FAD is also caused by mutations in the 
presenilin proteins.  Presenilin is one of four transmembrane proteins that comprise the 
γ-secretase complex (Figure 1.2).  These proteins play an important functional role in γ-
secretase activity as well as in biological functions outside the complex (De Strooper et 
al., 2012).   
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Figure 1.2: The γ-secretase complex.  This complex is comprised of four proteins: 
Presenilin 1 (PSEN1); nicastrin; APH-1; and PEN-2.  These proteins function together in 
order to cleave APP and Notch1.  The Notch intracellular domain (NICD), which is 
formed by Notch1 cleavage, translocates to the nucleus and regulates transcription of 
genes important in synaptic plasticity. 
 
It has been elucidated that the presenilins have critical, functional connections 
with γ-secretase activity.  De Strooper and colleagues discovered that PSEN1 was 
crucially involved in the production of Aβ (De Strooper et al., 1998).  It has been 
suggested that presenilin is a protease (Li et al., 2000), and essentially the catalytic 
subunit of γ-secretase (Wolfe et al., 1999).  Presenilins also direct the γ-secretase 
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cleavage of a protein involved in embryogenesis and development called Notch (De 
Strooper et al., 1999).  Before this discovery, γ-secretase inhibitors were thought to be a 
promising potential AD therapeutic, but inhibition of the enzyme led to a decrease in 
APP processing as well as blocked the cleavage of Notch.  Therefore, use of these 
inhibitors as a therapeutic intervention would lead to detrimental side effects in AD 
patients.  
 
Late onset FAD 
Late onset FAD is more closely linked to the apolipoprotein E (APOE) gene on 
chromosome 19.  APOE is a glycoprotein that exists in three different isoforms: E2, E3, 
and E4, separated by single amino acid substitutions.  Alleles, ε2, ε3, and ε4 that code 
for these isomers are present within the general population (Cedazo-Menguez and 
Cowburn, 2001).  Each person has 2 of the 3 possible alleles.  Prevalence rates for 
these alleles differ where 7% to 8% of individuals have the ε2 allele, 75% to 80% have 
the ε3 allele, and 14% to 15% have the ε4 allele (Zannis et al., 1993).  It has been 
demonstrated that heterozygous or homozygous expression of the ε4 allele leads to 
problems with membrane repair, steroid homeostasis, as well as the promotion of 
activities that lead to β-amyloid aggregation in AD brain (Schipper, 2011). 
Some researchers believe this genetic defect is more akin to susceptibility for AD 
than genetic determination.  Regardless, others believe as the population ages, people 
with symptoms of dementia should undergo genetic screening for presence of the 
APOE ε4 allele.  The likelihood of developing AD markedly increases with the 
expression of one or both copies of the ε4 allele (Hsiung and Sadovnick, 2007).  The 
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lifetime risk of developing AD may increase from 9% in an ε4-negative individual to 29% 
for carriers of a single ε4 allele (Seshandri et al., 1995).  Also, the presence of an ε4 
allele may hasten the appearance of AD symptoms by one to two decades when 
compared with non-carriers of the ε4 allele (Corder et al., 1993).   
 
Sporadic, late onset AD 
Although research has uncovered genetic mutations causing AD, much less 
progress has been made in identifying the factors that cause sporadic, late-onset AD.  
Most of the factors linked to sporadic AD are environmental, and “modifiable,” meaning 
one can prevent AD development by controlling certain aspects of his/her life.  For 
instance, there is an association between AD and cardiovascular disease.  The causes 
of cardiovascular disease are physical inactivity, diabetes, smoking, obesity, and high 
cholesterol (Kivipelto et al., 2005, Hendrie et al., 2006, Anstey et al., 2007, Yaffe, 2007, 
Whitmer et al., 2008, Wu et al., 2008, Pendlebury and Rothwell, 2009, Solomon et al., 
2009, Raji et al., 2010, Rusanen et al., 2010, Yaffe et al., 2011).  Therefore, one can 
decrease the likelihood of developing AD by changing daily habits such as increasing 
physical activity to improve cardiovascular health.  
Individuals that have experienced traumatic brain injury, head injury, and/or head 
trauma have demonstrated an increased risk for developing AD.  Reports have shown 
that people with moderate head injuries have double the risk of developing AD, while 
patients experiencing severe head trauma are 4.5 times more likely to develop AD than 
non-head injury individuals.  Moderate head injury is classified as a loss of 
consciousness for about 30 minutes, and severe is when the loss of consciousness 
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lasts 24 hours or more (Lye and Shores, 2000, Plassman et al., 2000).  People with 
careers in which repeated head injuries are common such as boxers, football players, 
and combat veterans have an increased risk of developing dementia, and have a 
greater chance of late-life cognitive impairments, as brains from a number of these 
individuals present post-mortem Tau tangles (Roberts et al., 1990, Groswasser et al., 
2002, Guskiewicz, 2005).  
Reports have also revealed that remaining mentally and socially active later in 
life (Hall et al., 2009) as well as eating a diet low in saturated fats may promote brain 
health (Polidori et al., 2009).  Unfortunately, there are not many studies that strongly 
support these conclusions, and the current investigations involve a small number of 
participants.  In the end, the greatest risk factor for AD is advancing age (Alzheimer’s 
Association, 2012).   
Taken as a whole, the risk factors leading to AD are multi-faceted.  Familial forms 
due to genetics are involved in AD development, as well as non-genetic associations.  
The realization that there are many causes of AD has made the discovery and 
development of therapeutic interventions extremely challenging. 
 
Current Treatments for AD 
 Currently, there are no therapeutic agents available that slow or reverse the 
progression of neurodegeneration in AD.  Available therapeutics only help to alleviate 
symptoms or maintain brain function for a short time before the inevitable cognitive 
decline.  At this time, there are five FDA-approved drugs on the market available for AD 
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patients.  These drugs can be classified into two categories, the cholinesterase 
modifiers and the glutamate antagonists. 
The first class of drugs, the cholinergic system modifiers, include 4 of the 5 FDA 
approved AD therapeutics (Health, 2010).  One of the most well known is the 
cholinesterase inhibitor Aricept (donepizel).  As cholinergic neurons degenerate 
throughout AD progression, there is a loss of cholinergic activity.  The cholinesterase 
inhibitors prevent degradation of acetylcholine by the enzyme acetylcholinesterase, 
which is thought to help cholinergic activity by increasing the concentration of synaptic 
acetylcholine, thereby making more neurotransmitter available to activate cholinergic 
receptors.  This class of inhibitors helps delay the loss of cognition, but it does not stop 
the neurons from degenerating.  After an average of 6 to 12 months of treatment, the 
cholinergic neuronal loss progresses to a point at which the cholinesterase inhibitors are 
no longer effective (Alzheimer's, 2011). 
 A second class of FDA-approved AD therapeutics is the glutamate antagonists.  
This class only contains one drug, Namenda (memantine).  Namenda binds to 
glutamatergic NMDA receptors, and prevents their activation.  It has been demonstrated 
that overactivity of the glutamatergic system in AD brain leads to neuronal damage.  
This drug reduces the activity of this system, which decreases the potential for neuronal 
loss.  At this time, Namenda is available to treat patients with moderate to severe AD 
symptoms (Health, 2010). 
 Currently, there is a wide array of novel therapeutics involved in clinical trials for 
AD treatment.  At this time, there are over 90 drugs undergoing clinical testing as 
potential AD therapeutics (Health, 2009).  Most have been unsuccessful at various 
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points in the clinical trial process.  For example, passive immunotherapeutics targeted 
to Aβ plaques demonstrated clearance of the peptides; however, 6% of the clinical trial 
participants developed sterile meningoencephalitis, which terminated the clinical trial 
(Orgogozo et al., 2003).  Later monoclonal antibodies raised against Aβ plaques, like 
bapineuzumab, demonstrated decreases in Aβ plaques in the brain, although no 
cognitive improvements were exhibited (Rinne et al., 2010).   
Other drugs, which target Tau aggregates such as Rember, have also been 
investigated for therapeutic potential.  This compound is a methylene blue derivative 
that has been proposed as an inhibitor of Tau aggregation (Atamna et al., 2008).  
Preliminary results from a Phase IIB clinical trial in the United Kingdom and Singapore 
demonstrate that Rember slowed AD progression by about 81% while patients given the 
placebo experienced cognitive decline.  A phase III clinical trial began in 2009, but the 
results from this study are not yet available (Bulic et al., 2008).   
 Since the drug treatments described above have had little to no success in truly 
modifying the disease process, there is still a need to find some other means of 
targeting the pathology and ultimate degeneration of neurons. Interestingly, promising 
targets have been found in currently FDA approved therapeutics for cancer.  For 
example, the N-terminal Hsp90 ATPase inhibitors, like geldanamycin (GA), have 
demonstrated promise in mouse models of AD, in which decreases in Tau aggregates 
were observed (Dou et al., 2003a, Luo et al., 2007).  More recently a group from Case 
Western Reserve University School of Medicine discovered that an FDA approved drug 
for skin cancer, bexarotene, led to the clearance of 50% of Aβ plaques from a mouse 
model of AD in 72 hours (Cramer et al., 2012).  The mechanisms of these potential 
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therapeutics improve overall cellular function by targeting systems that lead to AD 
pathology development.  The compounds stimulate cellular activities such as the protein 
quality control machinery, as opposed to focusing specifically on removing the 
characteristic protein aggregates associated with AD.  Therefore, focusing on 
developing therapeutics that enhance cellular activities may prove to be better AD 
treatments.  
 
2.  TAU PATHOLOGY IN NEURODEGENERATION 
As discussed earlier, neurodegeneration is caused by the accumulation of 
aberrant, misfolded proteins in or around neurons leading to synaptic dysfunction and 
subsequent cell death.  There are several neurodegenerative diseases, each 
characterized by aggregates of a specific protein.  For example, mutant huntingtin is the 
protein that accumulates in Huntington’s disease (HD), alpha-synuclein in Parkinson’s 
disease (PD), amyotrophic lateral sclerosis (ALS) is due to accumulation of misfolded 
SOD1 and TDP-43, and prion protein aggregates are present in prion diseases.  
Interestingly, the most common form of dementia, Alzheimer’s disease is characterized 
by two proteinaceous hallmarks: senile plaques (SPs) comprised of amyloid-β and 
neurofibrillary tangles (NFTs) produced by aggregation of Tau protein.  Most efforts for 
AD therapy have focused on Aβ rather than Tau, but recently Tau has gained much 
attention as a target, even though Tau is not mutated in AD. 
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Physiological Function of Tau 
 The microtubule-associated protein, Tau, is believed to be highly soluble, 
unstructured, heat stable, and hydrophilic (Barghorn and Mandelkow, 2002).  In 
mammalian brains, the major physiological function of the Tau protein is to promote 
assembly and stability of microtubules (Weingarten et al., 1975).  Tau binding to 
microtubules is dynamic, i.e., equilibrium is maintained between Tau bound to 
microtubules and Tau dissociated from microtubules.  This equilibrium is controlled by 
the degree of Tau phosphorylation (Lindwall and Cole, 1984, Alonso et al., 1994, Iqbal 
et al., 1994, Khatoon et al., 1995).  It has been suggested that this dynamic relationship 
may be essential for proper axonal transport (Ballatore et al., 2007). 
 Multiple post-translational modifications occur on different epitopes throughout 
the Tau protein.  As mentioned earlier, Tau binding to microtubules is controlled by 
phosphorylation, which occurs on serine/threonine residues and is directed to proline 
containing regions (Mazanetz and Fischer, 2007).  Other post-translational 
modifications such as glycosylation are thought to have an effect on Tau binding to 
microtubules (Arnold et al., 1996, Liu et al., 2004, Li et al., 2006), but phosphorylation is 
the most prominent mechanism (Mazanetz and Fischer, 2007).  Tau can have other 
post-translational modifications such as ubiquitination (Cripps et al., 2006), nitration 
(Mailliot et al., 2002), sumoylation (Dorval and Fraser, 2006, 2007), and glycation 
(Münch et al., 2002).  However, the role of these modifications in physiological Tau 
regulation or development of pathological forms of Tau have not been well 
characterized. 
 
 16 
 
‘with permission ‘ Hanger, DP, Anderton, BH, and Noble, W.  (2009).  Tau phosphorylation: the therapeutic challenge for 
neurodegenerative disease.  Trends in Molecular Medicine, 15(3), 112-119. 
Figure 1.3: Tau isoforms in the CNS and Tau phosphorylation sites.  (a) Six 
isoforms of Tau exist in human brain, where exons 2, 3, and 10 are alternatively spliced.  
Exons 2 and 3 (E2 and E3) code for two 28 amino acid inserts at the N-terminal portion 
of Tau.  When E2 and E3 are absent from Tau, it is designated as 0N.  When only E2 is 
present, it gives rise to 1N Tau isoforms.  If E2 and E3 are present in the protein, it 
results in 2N Tau isoforms.  M1-M4 denote the four microtubule binding repeat domains, 
and M2 is encoded by exon 10.  Absence of M2 results in 3R Tau and presence of M2 
leads to 4R Tau isoforms.  At the center of Tau is the proline –rich domain (PRD).  Tau 
isoforms can range in size from 352-441 amino acids as a result of alternative splicing.  
(b) Approximately 45 phosphorylation sites have been identified on Tau.  Most sites are 
present in the PRD and in the C-terminal region, with few sites found in the microtubule-
binding domain.  Sites labeled in orange indicate that identification occurred through 
phospho-specific antibody labeling, while the remaining sites were discovered through 
mass spectrometry and/or Edman degradation.   
Within neurons, tau is found predominantly in axons,
where it exists as a highly soluble, phosphorylated protein
that stabilizes and promotes the polymerization of micro-
tubules principally through the microtubule-binding
domain. The processes of phosphorylation and splicing of
tau are both developmentally regulated, with increased
phosphorylation occurring at embryonic and early devel-
opmental stages, a time at which only one tau isoform is
expressed, this being the smallest of the 3R variants lack-
ing the N-terminal inserts (Figure 1a) [5,6]. By contrast, all
six tau isoforms are present in mature brain, and phos-
phorylation of these tau species is relatively reduced com-
pared to that in foetal brain. Such developmentally
regulated changes in tau are likely to be related to an
increased requirement for neuronal plasticity during
embryogenesis and early development. Increased tau phos-
phorylation reduces the amount of microtubule-bound tau,
and 3R tau isoforms also bind less tightly than 4R tau to
microtubules. These factors thus support the notion that
the requirement for increased plasticity can be met by
elevated phosphorylation of 3R tau during periods of pro-
lific synaptogenesis. Furthermore, reduced plasticity is
apparent in fully differentiated adult neurons in which
4R tau isoforms are also expressed and tau phosphoryl-
ation is decreased [7].
Phosphorylation in the microtubule-binding domain
(residu s 244–368) of au is believ d to be crucial in reg-
ulating micro ubule stabilization. In particular, phos-
phorylation of the orthologous residues in adjacent
microtubule-binding repeats at S262 and S356 has been
suggested to detach tau frommicrotubules [8]. Phosphoryl-
ation of tau at sites distinct from the microtubule-binding
domainmight also be involved in regulation of cytoskeletal
stability because S214 and T231 in tau also reduce its
ability to bind to microtubules [9]. The putative binding
site of the peptidyl-prolyl isomerase Pin1 (peptidyl-prolyl
cis/trans isomerase, NIMA-interacting 1) is phosphory-
lated serine or threonine followed by proline, of which
there are 15 such motifs in tau, including T231-P232
[10]. However, Pin1 interacts only with phosphorylated
T231, with its binding resulting in a conformational change
that restores the ability of tau to bind to microtubules [11].
The concentration of phosphorylated T231 in cerebrospinal
fluid is associated with increased neurofibrillary tangle
load in AD, and a deficit in Pin1 results in neurodegenera-
tion, together indicating that phosphorylation at this resi-
duemight be significant in AD pathogenesis [12]. However,
the relative importance of specific individual phosphoryl-
ation sites (e.g. S214, T231, S262, S356) or subsets of
phosphorylation sites (e.g. in the microtubule-binding
Figure 1. Six isoforms of human CNS tau and phosphorylation sites detected o tau from Alzheimer brain. (a) Illustration of the six isoforms of human CNS tau, exons 2, 3,
and 10 are alternatively-spliced. Exons 2 and 3 (E2 and E3) encode two different inserts of 28 amino acids near the N-terminus of tau. Absence of E2 and E3 gives rise to 0N
tau isoforms, whereas inclusion of E2 produces 1N and inclusion of both E2 and E3 results in 2N tau isoforms. M1–M4 represent the four imperfect-repeat microtubule-
binding domains, M2 being encoded by exon 10. Lack of M2 produces 3R tau and inclusion results in 4R tau isoforms. The proline-rich domain (PRD) in the centre of the tau
polypeptide is indicated. Alternative-splicing produces tau isoforms ranging in size from 352–441 amino acids. (b) Positioning of phosphorylation sites on tau from
Alzheimer brain. Approximately 45 sites have been identified, and they seem to cluster in the PRD and in the C-terminal region, with few sites evident within the
microtubule-binding domain of tau. Six of the phosphorylation sites have been identified only by phospho-specific antibody labelling (indicated in orange); the remaining
phosphorylation sites have been identified by direct means (mass spectrometry and/or Edman degradation).
Review Trends in Molecular Medicine Vol.15 No.3
113
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Tau protein is located on chromosome 17 and contains 16 exons, of which 8 are 
alternatively spliced. These include exons 2, 3, 4A, 6, 8, 10, 13, and 14 (Goedert et al., 
1989a, Goedert et al., 1989b, Himmler, 1989, Wei and Andreadis, 1998, Gao et al., 
2000).  Six isoforms of Tau are present in adult brains, and all are derived from the 
same gene, MAPT, through alternative splicing.  The basic structure of Tau includes an 
N-terminal ‘projection domain’ that is followed by a proline-rich region.  Following the 
proline-rich domain is the C-terminal region, which contains the microtubule-binding 
domain.  This domain consists of either 3 or 4 repeats of a highly conserved tubulin-
binding motif (Lee et al., 1989).   
 The six isoforms of Tau differ from each other in two ways.  First, is by the 
number of microtubule binding motifs present at the C-terminal end of the protein.  
There can be either three or four repeats present, designated as 3R or 4R isoforms.  
The 3R and 4R isoforms are present in a one-to-one ratio in normal adult brains (Hong 
et al., 1998).  Secondly, they can differ by the absence or presence of two 29-amino 
acid-long sequences at the N-terminal region, which does not affect microtubule binding 
(Binder et al., 1985).  These two sequences are exons 2 and 3, and their absence or 
presence is indicated by -2-3 or +2+3.  However, one can be present without the other 
and this combination is designated -2+3 or +2-3.  The precise function of these multiple 
isoforms has not been established, although it has been discovered that the isoforms 
are differentially expressed throughout development (Ballatore et al., 2007). 
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Pathogenic Tau 
 One of the classic markers of neurodegeneration in Tauopathies is a decrease in 
Tau bound to microtubules leading to an increase in free, unbound Tau.  It is believed 
that increases in the cytosolic unbound Tau enhance the probability of conformational 
changes in Tau, eventually leading to aggregation and neurofibrillary tangle (NFT) 
formation (Kuret et al., 2005b).    Development of large NFTs from Tau is considered to 
be a multi-step process that first begins with the dissociation of Tau from the 
microtubules.  Abnormal dissociation of Tau is caused by various processes such as a 
decrease in dephosphorylation and/or an increase in phosphorylation.  The overall 
result is an increase in the free cytosolic Tau.  As the concentration of unbound Tau 
increases, small ‘pretangle’ deposits form, which lead to paired helical filaments (PHFs), 
and eventually NFTs (Ross and Poirier, 2004, Kuret et al., 2005a, Kuret et al., 2005b).  
‘Pretangle’ formation is not detectable by β-sheet dyes, unlike NFTs (Galvan et al., 
2001, Maeda et al., 2006, Maeda et al., 2007). 
 Importantly, increases in pathological Tau correlate with clinical manifestations of 
dementia, which is not the case with Aβ plaques (Alafuzoff et al., 1987, Arriagada et al., 
1992).  It has been discovered that individuals without clinical AD have as much Aβ 
plaque formation as age-matched individuals with AD, except the non-AD tissue lacks 
dystrophic neurites and NFTs present in the AD brains (Dickson et al., 1988, Katzman 
et al., 1988, Dickson et al., 1992).  Also, there is a group of diseases termed 
Tauopathies, which have AD-like neurofibrillary tangles without the presence of β-
amyloid plaques.  These are all due to specific mutations in the Tau gene discussed 
below.  Tauopathies are characterized by dementia and include frontal temporal 
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dementia with parkinsonism-linked to chromosome 17 (FTDP-17), progressive 
supranuclear palsy, Pick’s disease, and corticobasal degeneration (Hutton et al., 1998, 
Poorkaj et al., 1998, Spillantini et al., 1998).  Therefore, dementia can occur without β-
amyloid plaques further substantiating studies demonstrating that NFTs more closely 
correlate with neuronal loss than β-amyloid plaques.   
 Multiple stimuli are suspected of directly or indirectly influencing Tau aggregation.  
Mutations in Tau clearly lead to fibrillization, but aberrant kinase and phosphatase 
activities are also possible culprits.  Some data also suggest NFT formation occurs 
downstream from β-amyloid deposition as assumed by the β-amyloid cascade 
hypothesis. 
 
Mutations in Tau protein 
One of the most direct causes of abnormal Tau activity is the presence of 
mutations in the gene for Tau, MAPT.  Several research groups have carried out 
numerous genetic studies to demonstrate that mutations within MAPT lead to the 
development of FTDP-17 and other Tauopathies.  The FTDP-17 Tauopathy is 
characterized by the presence of hyperphosphorylated Tau that assembles into 
filaments (von Bergen et al., 2001, Goedert and Jakes, 2005).  Currently, there are over 
30 different mutations of the Tau gene identified in families with FTDP-17(Goedert and 
Jakes, 2005). 
Mutations within Tau cause many functional abnormalities, and there are multiple 
hypotheses advanced to explain how these mutations lead to abnormal Tau activity.  It 
has been suggested that certain mutations, i.e. the P301L mutation, increases Tau self-
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interaction, which predisposes Tau for filament assembly leading to rapid fibrillization 
(Nacharaju et al., 1999).  Other groups have demonstrated that mutated Tau is more 
easily phosphorylated and/or less susceptible to dephosphorylation (Alonso et al., 2004) 
than normal Tau.  Dayanandan and colleagues reported that Tau mutations led to 
impairments in the microtubule binding capabilities of the protein, thereby facilitating 
depolymerization of microtubules (Hong et al., 1998, Dayanandan et al., 1999). 
Intronic MAPT mutations, coding mutations in exon 10 (i.e. N279K), or missense 
mutations (i.e. P301L) may lead to changes in alternative splicing of Tau.  These 
changes could disrupt the one to one ratio of 3R to 4R Tau isoforms, causing an 
increase in the concentration of the 4R isoform.  Absence or presence of exon 10 also 
disrupts this ratio, and it has been demonstrated that the 4R Tau isoform is more 
susceptible to hyperphosphorylation (Alonso et al., 2004, Bhaskar et al., 2005).  Lastly, 
mutations within or adjacent to exon 10 hasten the formation of Tau filaments as these 
mutations are found within the microtubule binding domain of Tau (Nacharaju et al., 
1999).        
 
Kinases associated with Tau hyperphosphorylation 
 Under physiological conditions Tau contains 2 to 3 moles of phosphate per mole 
of protein (Kopke et al., 1993).  In AD, Tau becomes abnormally hyperphosphorylated 
(Iqbal et al., 1986) and forms the pathological PHFs and NFTs characteristic of the 
disease (Grundke-Iqbal et al., 1986a, Grundke-Iqbal et al., 1986b, Iqbal et al., 1989, 
Lee et al., 1991). Interestingly, individuals with AD have the same amount of normal 
Tau as age-matched controls; however, there is a 4 to 8-fold increase of 
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hyperphosphorylated Tau in AD brains (Khatoon et al., 1992, 1994).  Up to 40% of this 
aberrantly phosphorylated Tau occurs in the cytosol unassociated with PHFs or NFTs 
(Kopke et al., 1993).  As the hyperphosphorylated Tau increases, it begins to sequester 
normal Tau, further disrupting microtubule stability (Alonso et al., 1994, Alonso et al., 
1996).  
Over 38 serine/threonine residues on Tau are phosphorylated in AD (Morishima-
Kawashima et al., 1995, Hanger et al., 1998).  Multiple kinases have been implicated in 
the hyperphosphorylation of Tau including: glycogen synthase kinase-3β (GSK3β); 
cyclin-dependent kinase-5 (cdk5); microtubule-affinity-regulating kinase (Dokmanovic et 
al.); protein kinase A (PKA); casein kinase-1 (CK-1); mitogen-activated protein kinase 
(MAPK); and calcium and calmodulin-dependent protein kinase-II (CaMKII) (Pei et al., 
2003, Iqbal et al., 2005). 
GSK3β and cdk5 phosphorylate several of sites on Tau, and the majority of these 
sites are shared between the two kinases (Wang et al., 1998, Anderton et al., 2001).  
Both of these enzymes have high expression levels in the brain (Woodgett, 1990, Lew 
et al., 1994) and have been involved in all areas of NFT formation (Pei et al., 1998, Pei 
et al., 1999).  Transgenic mice overexpressing GSK3β have an increase in 
hyperphosphorylated Tau, which can be attenuated with GSK3β inhibition by lithium 
chloride (Perez et al., 2003, Tatebayashi et al., 2004).  
In order for cdk5 to be active, it requires a small fragment p35 or its proteolytic 
product p25, which results from calpain cleavage of p35 (Kushakawa et al., 2000).  The 
production of p25 significantly increases the activity of cdk5.  A transgenic mouse model 
 
 22 
overexpressing p25 demonstrates increases in hyperphosphorylated Tau as a result of 
abnormal cdk5 activity (Cruz et al., 2003, Noble et al., 2003). 
Phosphatases have also been implicated in the development of 
hyperphosphorylated Tau, including protein phosphatase-2A (PP-2A) and protein 
phosphatase-1 (PP-1).  It has been demonstrated that their activity is decreased by 
about 20% in AD brain (Gong et al., 1993, Gong et al., 1995).  These enzymes are 
responsible for dephosphorylating about 90% of the serine/threonine sites in mammals 
(Oliver and Shenolikar, 1998).   
 
β-amyloid cascade hypothesis and Tau pathology  
 The β-amyloid Cascade Hypothesis is one of the most accepted models of AD 
progression.  It states that Aβ generation is the primary pathological event leading to 
NFT formation and dementia (Hardy and Higgins, 1992, Hardy and Selkoe, 2002).  
Many studies substantiate this hypothesis, in particular, studies on the triple transgenic 
(3xTgAD) mouse model, which contains the APP Swedish, PSEN1, and P301L Tau 
mutations (APPswe-PS1M146V-TauP301L) (Oddo et al., 2003b).  This model develops 
Aβ pathology before the deposition of Tau tangles, and the 3xTgAD model had more 
NFT pathology than the double transgenic model (Tg2x).  This model contains the 
PSEN1 and P301L mutations, but not the Aβ producing APP-Swedish mutation (Oddo 
et al., 2003a).  A second study that supports the Amyloid Cascade Hypothesis involved 
intracerebral injections of Aβ into a P301L transgenic mouse model.  Injections of the 
aggregated Aβ exacerbated the Tau pathology in the mutant Tau mouse model (Gotz et 
al., 2001).  P301L transgenic mice crossed with mice containing the APP-Swedish plus 
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the London mutations also developed more prominent Tau pathology than mice 
expressing the P301L mutation alone (Lewis et al., 2000).   
A third experimental procedure that supports the Amyloid Cascade Hypothesis is 
the use of Aβ peptides to induce toxicity in cellular models.  The addition of Aβ peptides 
also stimulates Tau phosphorylation in cell culture (Li et al., 2003, Blurton-Jones and 
LaFerla, 2006, Oddo et al., 2006, Seyb et al., 2007). 
 Unfortunately, results from mouse and cell culture studies do not correlate with 
human data.  First, individuals without AD develop Aβ plaques similar to individuals with 
AD, and the former group does not show neurofibrillary pathology (Katzman et al., 
1988).  Secondly, higher levels of Aβ burden are observed in hereditary cerebral 
hemorrhage with amyloid pathology, Dutch type, but Tau pathology does not develop 
with the disease (Levy et al., 1990).  Third, as mentioned before, individuals affected 
with the Tauopathies exhibit a demented phenotype, but only produce neurofibrillary 
pathology (Hutton et al., 1998).  Finally, cultured cells expressing the PSEN1 mutation 
do not regenerate Aβ peptides after levels of Aβ peptides were depleted (Shioi et al., 
2007). 
 Overall, studies examining the β-amyloid Cascade Hypothesis are still a matter of 
some controversy.  Although some studies support the idea that Aβ leads to Tau 
pathology, the human studies do not substantiate these conclusions.  At this point in 
time, AD research certainly makes it clear that this disease is multi-faceted, and the β-
amyloid Cascade Hypothesis may be too simplistic to describe disease progression. 
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3.  MOLECULAR CHAPERONES AND THERAPEUTICS FOR PROTEIN 
MISFOLDING DISEASES 
 Molecular chaperones are families of highly conserved proteins that mediate the 
folding of nascent proteins, or re-folding of misfolded proteins, but are not part of the 
final product (Muchowski and Wacker, 2005a).  These proteins are essential for 
numerous cellular processes such as proteasomal degradation, lysosomal autophagy, 
signal transduction, and protein transport (Hartl and Hayer-Hartl, 2002).  When stressful 
cellular events occur such as temperature elevation, pH changes, or reactive oxygen 
species (ROS) generation, the cell stimulates the production of a subset of molecular 
chaperones called the heat shock proteins (HSPs).  The HSPs are essential in 
recovering proteins damaged from cellular stress (Lindquist, 1986).  Six different 
families of HSPs exist, and they are classified by their molecular weight in kilodaltons 
(kDa).  These families include: Hsp100, Hsp90, Hsp70, Hsp60, Hsp40, and HSPs that 
weigh less than 40 kDa called the small HSPs (sHSPs) (Muchowski, 2002).  There are 
many isoforms within each of these families, some of which are constitutively expressed 
and some are inducible.  
 In addition to the molecular chaperones, there are groups of proteins called co-
chaperones that assist the primary molecular chaperones in refolding or clearing the 
targeted protein.  Through their interactions with the molecular chaperone, they can 
help determine the fate of the faulty protein, i.e., whether it will be removed from the cell 
through degradation or whether it will be re-folded into its native conformation.  There 
are many different co-chaperones, and in our studies we will only focus on three such 
proteins: BAG1, BAG2, and CHIP.   
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Heat Shock Proteins and the Heat Shock Response 
 As previously mentioned, the heat shock proteins play an important role in the 
ability of the cell to respond to cellular stresses like increases in temperature, changes 
in pH, or oxidative insults.  When these cell stresses occur, a cytosolic transcription 
factor, heat shock factor-1 (HSF-1), is released from its binding partner, Hsp90.  Upon 
release, HSF-1 becomes phosphorylated, trimerizes, and enters the nucleus.  Once 
inside the nucleus, HSF-1 binds to the heat shock response element (HSRE) on several 
genes, and increases the transcription of mRNA for additional proteins involved in 
protein folding or protein degradation such as Hsp90, Hsp70, and Hsp40.  These HSPs 
form complexes with other proteins and provide assistance in refolding denatured 
proteins and targeting non-repairable proteins for degradation (Ferrarini et al., 1992).   
  
Hsp90 family 
The Hsp90 family of molecular chaperones makes up 1-2% of all cytosolic 
proteins in a typical cell.  This family consists of four isoforms that control the activity of 
a vast array of signaling proteins.  These proteins refold and stabilize misfolded proteins 
(Muchowski and Wacker, 2005b) as well as signal the ubiquitination and degradation of 
proteins beyond repair (Ferrarini et al., 1992).  These four isoforms include: Hsp90α, the 
inducible form found in the cytosol; Hsp90β, the constitutive form also found in the 
cytosol; 94kDa glucose-regulated protein (Grp94) localized in the endoplasmic 
reticulum; and Hsp75/tumor necrosis factor receptor associated protein-1 (TRAP-1) 
confined to the mitochondrial matrix (Maloney and Workman, 2002). 
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Figure 1.4: Structure of Hsp90.  The Hsp90 protein consists of 677 amino acids and 
contains three different domains: N-terminal domain (NTD; red); the middle domain 
(MD; green); and the C-terminal domain (CTD; blue).  An ATP binding site is located at 
the NTD, and is represented by white and blue balls.  Hsp90 functions as a dimer with 
client proteins.  Client proteins interact with the dimeric protein at the MD.  The protein 
dimer forms through interactions at the CTD. 
   
 In its active form, Hsp90 exists as a dimer.  As shown in Figure 1.4, Hsp90 is 
composed of three different domains: an N-terminal domain (NTD), which contains an 
ATP binding site; the middle domain (MD) where client binding occurs; and the C-
terminal domain (CTD), which is the site of dimerization (Pearl and Prodromou, 2006).  
Each of these regions performs important roles in the activity of Hsp90. 
 Within the NTD is the nucleotide-binding pocket, which is highly conserved 
across species (Bergerat et al., 1997). Binding and hydrolysis of ATP at this site results 
in multiple conformational changes in Hsp90.   These conformations permit the Hsp90 
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to bind and interact with a sizeable group of structurally diverse client proteins, as well 
as large complexes that contain other molecular chaperones and co-chaperones 
(Krukenberg et al., 2011).    
 Client protein binding to Hsp90 occurs at the MD.  This region contains a 
catalytic loop, which is critical in the hydrolysis of ATP at the NTD.  The activity of co-
chaperones that hydrolyze ATP can also be increased by the catalytic loop of the MD 
(Meyer et al., 2003b).     
Not only is the CTD of Hsp90 the portion where dimerization occurs, it also plays 
an important role in regulating activities at the NTD.  There is a C-terminal motif 
(MEEVD) that promotes co-chaperone binding.  Co-chaperones that bind at this motif 
regulate Hsp90 activity.  The type of co-chaperone that binds determines the outcome.  
These co-chaperones can aid in client folding, modulate Hsp90 ATPase activity, 
determine recruitment of specific client proteins, and stimulate maturation of substrates 
(Krukenberg et al., 2011).  For example, when the co-chaperone Tom70 binds to 
Hsp90, Tom70 stimulates Hsp90 to assist in mitochondrial transport (Wandinger et al., 
2008).    
 
Hsp70 family 
 This family of 70kDa proteins is the most evolutionarily conserved (Hunt and 
Morimoto, 1985).  There have been eleven members of the Hsp70 family identified, 
each encoded in a different gene (Brocchieri et al., 2008), and these homologs exhibit 
tissue specific expression levels and differences in sub-cellular localization (Tavaria et 
al., 1996).  Most Hsp70 homologs contain an ATPase domain, a peptide binding 
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domain, and a middle region containing protease sensitive sites (Bukau et al., 2006, 
Brocchieri et al., 2008).  The expression level of the Hsp70 proteins differs depending 
on the cellular situation.  Most Hsp70 proteins are constitutively expressed, while a few 
are inducible forms with increased expression occurring during cellular stress events 
(Daugaard et al., 2007).  Hsp70 proteins are critical for many cellular functions: 
degradation of faulty or ‘misfolded’ proteins; nascent folding of proteins and refolding of 
abnormal proteins; and maintenance of cellular homeostasis by controlling proteins 
during stress events such as high pH levels, ischemia, high temperature, or 
inflammation (Lindquist and Craig, 1988).   
The ATPase domain of Hsp70 is responsible for substrate binding and release. 
Hsp70 is bound to a substrate with low affinity when it is in its ATP binding state, and 
the substrate binds to Hsp70 with high affinity when it is in the ADP state. This ATPase 
switching is mediated by co-chaperones that regulate the duration of the Hsp70-
substrate bound complex (Erbse et al., 2004).  These co-chaperones play a very 
important role in targeting Hsp70 to sites involved in specific cellular functions at 
multiple regions in the cells. 
Hsp70 proteins never work alone.  In order for it to be fully active, Hsp70 requires 
a co-chaperone.  These co-chaperones include Hsp40 and nucleotide exchange factors 
(NEFs) such as the Bcl-2-associated athanogene (BAG) proteins.  The type of co-
chaperone bound to Hsp70 will determine the ultimate outcome (Kampinga and Craig, 
2010) such as BAG2 association with Hsp70, which will lead to ubiquitin independent 
degradation of client proteins (Carrettiero et al., 2009).  
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Hsp60 family 
 Hsp60 is generally found in the mitochondria; however, recent evidence suggests 
that some Hsp60 also resides in the cytosol (Chandra et al., 2007).  Within the 
mitochondria, Hsp60 interacts with Hsp10, an sHSP, to regulate nascent polypeptide 
folding into native conformations (Naylor and Hartl, 2001, Ranford and Henderson, 
2002, Meyer et al., 2003a).  Hsp60 also interacts with mitochondrial Hsp70, also called 
mortalin, to regulate apoptosis (Wadhwa et al., 2005, Deocaris et al., 2006, Kaul et al., 
2006).  In addition to regulating protein folding, Hsp60 also plays a role in protein 
trafficking (Deocaris et al., 2006) and peptide-hormone signaling (Czarnecka et al., 
2006).  Cytosolic Hsp60 and mitochondrial Hsp60 function in pro-apoptotic and pro-
survival pathways depending on the cellular conditions (Chandra et al., 2007).  For 
example, Hsp60 controls key pathways involved in tumor cell development, which 
provides an attractive protein for cancer therapy (Cappello et al., 2008). 
 
Hsp40 family 
 The Hsp40 family of proteins is characterized by the presence of a highly 
conserved 70 amino acid region called the ‘J domain’.  The primary function of this 
domain is to regulate the ATPase activity of Hsp70 (Craig et al., 2006, Hageman and 
Kampinga, 2009).  There are about 41 different Hsp40 proteins that bind to the ATPase 
domain of Hsp70 (Kampinga and Craig, 2010). The Hsp40 that interacts with Hsp70 
directly determines which client protein is present in the complex (Craig et al., 2006, 
Hageman and Kampinga, 2009). For example, the ribosome-associated J protein DnaJ 
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subfamily C member 2 (DNAJC2) recruits Hsp70 to the endoplasmic reticulum (ER) in 
order to assist in later stages of polypeptide formation (Hundley et al., 2005). 
 
Small HSPs family 
 The small heat shock proteins (sHSPs) are considered “housekeeping” proteins 
as they play essential roles in regulating cellular functions.  Hsp27 has been 
demonstrated to promote protein folding as well as to regulate apoptosis.  For example, 
Hsp27 blocks cytochrome c release from the mitochondria by interacting with 
phosphatidylinositol 3 kinase (PI3K) eventually leading to the phosphorylation of Bcl-2-
associated-X protein (BAX) (Havasi et al., 2008).  Hsp22 prevents protein aggregation 
and participates in apoptosis.  Another sHSPs, Hsp20 displays chaperone activity and 
regulates contraction of smooth muscle cells (Mymrikov et al., 2011).  
 
Molecular Co-Chaperones 
 Co-chaperones are non-client proteins that bind to Hsp70 or Hsp90 and regulate 
their cellular actions.  Many proteins bind to the nucleotide-binding site present on both 
Hsp70 and Hsp90, and regulate client binding.  Others structurally link Hsp70 or Hsp90 
to their desired client protein.  For example, Aha1 interacts with Hsp90 and stimulates 
the ATPase activity of Hsp90 (Panaretou et al., 2002). 
Although there are over 100 different co-chaperones, almost all can be placed 
into one of two different categories based on their structural features.  There are the 
Hsp40 proteins (J proteins) that only interact with Hsp70, or the TRP binding proteins 
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that can interact with both Hsp70 and Hsp90 (Caplan, 2003).  In this section, three co-
chaperones will be discussed in their relationship to Hsp70: BAG1, BAG2, and CHIP.  
 
BAG proteins 
 One family of co-chaperones that interacts with Hsp70 is the Bcl-2-associated 
athanogene (BAG) group. The BAG family of proteins consists of 6 different members, 4 
of which have been shown to associate with Hsp70 (Takayama and Reed, 2001).  
These proteins share a BAG domain that consists of a conserved sequence of about 
110 amino acids located at the C-terminal region; this region interacts with the Hsp70 
ATPase domain (Takayama et al., 1999).  BAG proteins can induce the release of a 
bound substrate from Hsp70 by mediating nucleotide-exchange (Sonderman et al., 
2001).  These proteins also assist in Hsp70-dependent protein degradation (Takayama 
and Reed, 2001).  Here, two BAG proteins will be discussed, with regard to in their 
relationship with Hsp70 and its client protein Tau.  
 
BAG1 
There are three human and two mouse BAG1 isoforms (Takayama et al., 1998).  
It has been demonstrated that BAG1 interacts with Hsp70 and Tau (Luders et al., 2000), 
and increases Hsp70 refolding activity in neurons (Liman et al., 2005).  BAG-1 is crucial 
in the formation and maintenance of neurons (Gotz et al., 2005).  Conversely, it has 
also been reported that BAG1 binding to Hsp70/substrate complexes suppresses the 
refolding activity of Hsp70 (Takayama et al., 1997).  It has been shown in mouse 
models of Alzheimer’s disease that BAG1 is highly expressed in neurons where Tau 
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tangles reside.  This increased expression of BAG1 does not prevent ubiquitination, but 
it can inhibit Tau degradation via the 20S proteasome (Elliott et al., 2007).  
BAG1 is different from the other BAG proteins in that it has an ubiquitin-like 
domain.  This domain is present at the N-terminus of the protein and is correlated with 
ubiquitin-dependent degradation of proteins (Demand et al., 2001).  BAG1 and the 
ubiquitin-ligase, carboxy terminus of Hsc70-binding protein (CHIP), simultaneously bind 
to Hsp70 to ubiquitinate client proteins and target them for degradation in the 
proteasome (Hartl and Hayer-Hartl, 2002, Gamerdinger et al., 2011).    
 
BAG2 
 Another member of the BAG family, BAG2, has been reported to play a critical 
role in mediating a highly efficient mode of Tau degradation through ubiquitin-
independent mechanisms.  It has been demonstrated that the BAG2/Hsp70 complex 
can tether hyperphosphorylated Tau from microtubules to the proteasome for 
degradation without the ubiquitination of Tau (Carrettiero et al., 2009).  Lukiw and 
colleagues have shown that expression of BAG2 is inhibited by miR-128, a microRNA 
that is up-regulated in Alzheimer’s disease (Lukiw, 2007), thereby preventing BAG2 
associated removal of aggregated Tau. 
Although there are not many studies demonstrating the roles of BAG proteins in 
relation to Tau, it cannot be denied that there is some evidence suggesting an 
interaction between the BAG proteins and HSP70 in the context of Alzheimer’s disease.  
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CHIP 
 One Hsp70 co-chaperone that has been widely studied in relation to Tau 
pathology is the carboxy terminus of Hsc70-binding protein (CHIP).  This protein has a 
tetratricopeptide repeat (TPR) domain that associates with Hsp70 protein (Ballinger et 
al., 1999) and a U-box domain that has E3, or ubiquitin-ligase activity.  The E3 enzymes 
catalyze the third and final step of substrate recognition by the proteasome 
(Hatakeyama et al., 2004).  CHIP interacts with Hsp70, Hsp90, and Tau, although its 
most prominent effect is observed through Hsp70 (Grelle et al., 2006).  CHIP binding to 
Hsp70 abrogates the ATPase refolding activity of HSP70 (Ballinger et al., 1999).   
CHIP levels are elevated in human Alzheimer’s disease tissue (Sahara et al., 
2005) suggesting that CHIP plays a part in the formation of Tau tangles.  This ubiquitin-
ligase protein mediates ubiquitination of Tau and somehow increases Tau aggregation 
(Petrucelli et al., 2004a). CHIP also associates with BAG1 and controls crosstalk 
between the ubiquitin-proteasome system and chaperone proteins (Luders et al., 2000).  
Intriguingly, BAG2 inhibits CHIP activity by preventing E3 ligase activation (Arndt et al., 
2005).  Dickey and colleagues used an in vitro model demonstrating that CHIP is a 
critical modulator of hyperphosphorylated Tau levels when HSF-1 is absent (Dickey et 
al., 2007). 
Based on current knowledge, the co-chaperones are essential in regulating the 
activity of molecular chaperones.  The way these proteins interact with the molecular 
chaperone complexes is multi-faceted, and appears to depend on what proteins are 
present in the complex.  The complexity of these interactions not withstanding, a better 
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understanding of the role these proteins play in maintaining the quality of proteins will 
help in the development of efficacious therapeutics for AD. 
  
4.  HSP90 MODULATION AS A POTENTIAL THERAPEUTIC FOR AD 
 As previously mentioned, many neurodegenerative diseases are characterized 
by the accumulation of aberrant proteins.  Tauopathies, such as FTDP-17 and AD, have 
neuronal loss due to the presence of hyperphosphorylated Tau protein.  
Hyperphosphorylated Tau is unable to properly associate with microtubules, and 
disrupts the critical process of exoplasmic transport.  In addition, the dissociated Tau 
begins to form aggregates, the NFTs, and forces the cell to try to function in the 
presence of these aggregated proteins.   
One possible culprit responsible for NFT development may be ineffective 
chaperones.   For example, reduced expression or activity of molecular chaperones 
would be expected to lead to Tau fibrils.  Some groups have shown that the protein 
degradation systems, particularly the proteasome that would normally remove these 
toxic aggregates are overburdened or functioning improperly.  This dysregulation of the 
proteasome is a part of aging (Layfield et al., 2003) and thus the proteins of the 
degradation pathway cannot keep up with the need to clear aggregated Tau.  Also 
reported are increased levels of the ubiquitin-ligase, CHIP, in AD brains (Sahara et al., 
2005).  An increase of CHIP, in conjunction with a decrease in proteasome activity, 
supports the finding that Tau aggregates are poly- and mono-ubiquitinated, but are not 
cleared (Cripps et al., 2006).  One group has shown a decrease in Hsp70 and Hsp90 
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protein levels in cellular, rodent, and human disease models of ‘Tauopathies’ (Dou et 
al., 2003b).  
 
Hsp90 Inhibition in Cancer 
 Hsp90 inhibitors were first designed as cancer treatments.  Proteomic studies 
revealed that many tumor types overexpress HSPs, thereby using this system to fold 
nascent client proteins required for proliferation.  In order to stop the proliferation of 
cancer cells, researchers designed therapeutic agents to modulate the folding of these 
molecules (Khalil et al., 2011).  In fact, early stages of HSP-designed cancer therapy 
used hyperthermia as an effective intervention (Lindquist, 1986).   
 The classic HSP family involved in cancer is HSP90 (Sreedhar et al., 2004).  It is 
believed that cancer cells take control of the protein quality control machinery to start 
producing cancer cell polypeptides (Pockley, 2001).   Several small molecule inhibitors 
demonstrate strong anti-tumor capabilities in multiple malignancies (Taldone et al., 
2008).  These inhibitors prevent the cells from folding the proteins contributing to 
malignancy.  Currently, there are 14 Hsp90 inhibitors in clinical trials to be used as 
single agents or in combination therapy to treat cancer (Porter et al., 2010).  These 
clinical trials include the Hsp90 inhibitor 17-allylamino-17-demethoxygeldanamycin (17-
AAG), a derivative of the ansamycin antibiotic geldanamycin (GA).  17-AAG has already 
demonstrated promising results in various Phase I and Phase II clinical trials (Banerji et 
al., 2005, Goetz et al., 2005, Grem et al., 2005, Heath et al., 2005, Ramanathan et al., 
2005).   
 
 
 36 
Cancer Therapeutics Transition to AD 
 Similar to cancer, overexpression of HSPs is demonstrated in multiple 
neurodegenerative disorders, including AD, possibly as a compensatory response to the 
misfolded protein aggregates (Perez et al., 1991, Anthony et al., 2003).  This 
overexpression of HSPs in neurodegenerative diseases led researchers to design a 
group of novel drugs that could modulate the activity of Hsp90 and activate the protein 
folding or clearance cascade.  At this time there are two different domains within Hsp90 
where drugs are being targeted; agents designed to inhibit the N-terminal ATPase 
activity of Hsp90 or agents to modulate the C-terminal region of Hsp90.   
 Although Hsp90 inhibitors are designed against different domains of the protein, 
the hypothetical effect of the drug on modulating the activity of molecular chaperones by 
activating the heat shock response is considered similar.  The schematic in Figure 1.5 
shows the theoretical outcome of Hsp90 inhibition.  For instance, when an Hsp90 
inhibitor enters the cytosol of the cell, it blocks Hsp90, which releases proteins bound in 
the complex including the transcription factor, HSF-1.  With HSF-1 being free from 
Hsp90, it can be phosphorylated, trimerized, and translocated to the nucleus.  Once in 
the nucleus, it binds to the heat shock response element (HSRE) and up-regulates 
transcription of molecular chaperones important to maintaining protein quality.  
Concurrently, other molecular chaperones i.e. Hsp70 and Hsp40 originally bound to the 
Hsp90 complex are also free to assist faulty proteins. 
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Figure 1.5: A hypothetical schematic of Hsp90 inhibition.  An Hsp90 inhibitor enters 
the cell where it dissociates the Hsp90 complex, freeing the transcription factor, HSF-1.  
Once free, HSF-1 is phosphorylated, trimerized, and translocated to the nucleus where 
it binds to the heat shock response element (nGAAn).  This stimulates an increase in 
transcription of molecular chaperones involved in protein folding and degradation.  
Subsequently, the Hsp90 inhibitor frees other molecular chaperones in the Hsp90 
complex i.e. Hsp70 and Hsp40, which allows them to interact with faulty proteins and 
return them to their native conformation. 
 
 In the next two sections, compounds designed against the N-terminal and C-
terminal portions of Hsp90 will be described in their relation to neurodegeneration, 
specifically AD.   
 
N-terminal Hsp90 Inhibition in Neurodegeneration 
 The factors that lead to the deposition of SPs and NFTs in the affected AD brain, 
first develop as cellular dysfunctions (Chui et al., 1999, Hsia et al., 1999, Moechars et 
al., 1999, Kumar-Singh et al., 2000).  Since the HSPs play an important role in 
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maintaining proper cellular function, and there are promising reports of Hsp90 inhibitors 
as cancer therapeutics, it is logical to propose similar roles for Hsp90 inhibitors in 
neurodegenerative diseases (Luo et al., 2008).      
 The best known Hsp90 inhibitor is geldanamycin (GA), an ansamycin antibiotic 
that was first used as an antifungal medication (DeBoer et al., 1970). Greengard’s group 
used in vitro cell models transfected with abnormal Tau, and treated them with GA to 
demonstrate dose dependent decreases of insoluble Tau, as well as dose dependent 
increases in Hsp70 and Hsp90 protein levels.  GA treatment decreased the levels of 
hyperphosphorylated Tau induced by okadaic acid (OA), a PP2A inhibitor (Dou et al., 
2003).  Interestingly, a microtubule-binding assay showed that GA increased the 
association of Tau with microtubules while simultaneously decreasing levels of 
aggregated Tau (Dou et al., 2003).  These findings support the idea that Hsp90 
inhibitors are potential candidates for AD treatment. 
 Further studies with GA were continued in other labs studying neurodegenerative 
diseases.  Petrucelli and colleagues used GA and the addition of pure HSF-1 protein to 
reveal increases in Hsp70 levels in a human neuroblastoma cell line expressing 
endogenous Tau.  These results demonstrated that the increases in Hsp70 occur 
through an HSF-1 mediated pathway.  This group also revealed that CHIP mediated 
ubiquitination of Tau, but the presence of Hsp70 prevented CHIP from ubiquitinating 
Tau.  Overexpression of Hsp70 in a mouse model at 30 months of age demonstrated a 
decrease in Tau when compared to age matched mice without the Hsp70 transgene 
(Petrucelli et al., 2004).  Overall, the results from Greengard’s and Petrucelli’s groups 
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validate the idea that Hsp90 inhibitors stimulate the heat shock response to assist cells 
in clearing aggregated proteins.      
Although a potent modulator of the heat shock response, GA is hepatotoxic 
(Supko et al., 1995).  This led to the development of the derivatives, such as 17-AAG, 
which demonstrates the same biological behaviors as GA (Schulte and Neckers, 1998), 
but is less toxic to the liver (Page et al., 1997).  Using 17-AAG, and PU24Cl, a synthetic 
derivative of GA, Greengard’s group demonstrated dose-dependent increases in Hsp70 
protein levels as well as dose-dependent decreases in hyperphosphorylated Tau 
epitopes in COS-7 cells containing mutant P301L Tau (Luo et al., 2007).  A blood brain 
barrier (BBB) permeable derivative of GA, PU-DZ8, also displayed decreases of 
hyperphosphorylated Tau in a mouse model expressing mutant P301L Tau (Luo et al., 
2007).  
Other groups have also developed non-toxic, small molecule inhibitors of Hsp90.  
Dickey and colleagues developed a BBB permeable Hsp90 inhibitor called EC-102.  
This compound displayed robust increases in Hsp70, Hsp40 and Hsp27 levels in CHO 
cells transfected with mutant P301L Tau.  Using the same transfected P301L Tau cell 
model, this group also demonstrated decreases in hyperphosphorylated and total Tau 
levels.  These changes were the same or similar to cells treated with 17-AAG (Dickey et 
al., 2006). 
In 2007, Dickey’s group published results regarding the small molecule inhibitor 
of Hsp90, EC102.  EC102 increased Hsp70 levels in CD-1 mouse brains while 
concurrently decreasing hyperphosphorylated Tau levels in HeLa cells transfected with 
mutant Tau.  A cell model with siRNA directed against CHIP prevented EC102 mediated 
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decreases in phospho-Tau.  Hsp40 knockdown also prevented EC102 decreases in 
phospho-Tau (Dickey et al., 2007).  These results suggest that EC102 requires CHIP 
and Hsp40 to modulate the removal of hyperphosphorylated Tau.     
As the compounds discussed here are all derivatives of the two well-described N-
terminal Hsp90 inhibitors, GA and 17-AAG, it is possible that although these agents 
show promise with acute treatment in animal models, there is potential for toxicity with 
chronic treatment.  In order for a neurodegenerative therapeutic to be effective, the drug 
will most likely need to be administered for years.  Therefore, it is necessary to develop 
a compound that will stimulate the heat shock response, but will remain non-toxic over 
long periods of treatment.  Keeping this in mind, Hsp90 inhibitors directed at the C-
terminus of the protein were developed and assessed for their efficacy as a treatment 
for AD.  
 
C-terminal Hsp90 Inhibition in Neurodegeneration 
Given that N-terminal Hsp90 inhibitors are toxic at low doses, researchers 
searched for other methods to modulate Hsp90 activity.  In 2000, a group demonstrated 
that novobiocin (Figure 1.6), an inhibitor of bacterial DNA gyrase, bound to the C-
terminus of Hsp90 with low affinity (Marcu et al., 2000a, Marcu et al., 2000b).  
Derivatives for novobiocin were developed in order to increase potency, as well as to 
assess the ability of these analogs to provide protection in models of AD. 
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Figure 1.6: Structure of Novobiocin and the Novobiocin derivatives, A4 and KU-32 
 
One of the first non-toxic novobiocin derivatives with high affinity binding to the C-
terminus of Hsp90 was A4 (Figure 1.6).  This compound dose-dependently protected 
primary rat neurons from Aβ induced toxicity, and dose dependently increased levels of 
Hsp70 similar to GA.  Most importantly, this analog was not toxic to primary neurons at 
concentrations up to 10 μM, whereas the same concentration of GA induced 80% cell 
death (Ansar et al., 2007).  
As more derivatives of novobiocin were developed, a second potent analog was 
discovered, designated KU-32 (Figure 1.6).  Early results regarding this compound 
demonstrated that it was protective against Aβ-toxicity in undifferentiated and 
differentiated neuroblastoma cells (Lu et al., 2008).  Further studies involving KU-32 
show that it dose-dependently increased Hsp70 levels in MCF7 cells, and provided 
dose-dependent protection against demyelination and glucose toxicity in peripheral 
neurons.  However, the most promising results from this study indicate that KU-32 
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Scheme 1. 
 
The major Hsp, Hsp90, exerts its e!ects through a wide-
array of co-chaperones, partner proteins, and immuno-
philins, forming the major chaperone system responsible
for protecting cells against toxicity resulting from the
accumulation of protein aggregates. Based on these
properties, it was proposed that increased chaperone
activity may refold aggregating proteins and have ther-
apeutic applications for the treatment of neurodegener-
ative diseases. Recently, Greengard and coworkers
demonstrated that increased Hsp70 and Hsp90 levels
resulted in decreased tau aggregates and provided neu-
roprotection in cells expressing mutant tau that becomes
hyperphosphorylated as in AD brain.6 Consequently,
regulation of Hsp70 and Hsp90 expression levels has
been pursued as a novel approach toward the treatment
of diseases caused by protein aggregates.
Cellular stresses such as elevated temperature, abnor-
mal pH, oxidative stress, and malignancy result in
the denaturation of native proteins as well as the over-
expression of molecular chaperones to refold these
structures or target them for degradation via the ubiq-
uitin-proteasome pathway.7–9 Upon exposure to these
stresses, Hsp90 and Hsp70 levels are increased to
assist in the renaturation process. The expression of
these heat shock proteins is tightly regulated by the
transcription factor heat shock factor 1 (HSF1).
Under normal conditions, Hsp90 forms a stable
complex with HSF1 and prevents the transcriptional
activation of the heat shock response.10 Cellular
stressors result in destabilization of Hsp90/HSF1, the
subsequent trimerization and phosphorylation of
HSF1, and its translocation to the nucleus, where it
induces Hsp expression.11,12 Another key protein
in the Hsp90 heteroprotein complex is the co-
chaperone CHIP (carboxyl terminus of the Hsc70-
interacting protein).13 CHIP binds Hsp70 through its
tetratricopeptide repeat (TPR) domain and also pos-
sesses intrinsic ubiquitin ligase activity, suggesting a
direct link between the chaperone and the ubiquitin-
proteasome pathway which may modulate the cellular
equilibrium of protein folding and degradation.14
Previously identified inhibitors of Hsp90 include
geldanamycin (GA, Fig. 1) and its derivatives, which
bind to the N-terminal ATP-binding pocket. These
N-terminal inhibitors manifest their activity by com-
petitive inhibition of ATP, which serves as the req-
uisite source of energy for the Hsp90-mediated
protein folding process. The concentration of N-ter-
minal inhibitors required to induce degradation of
Hsp90-dependent client proteins is approximately
equal to that needed to increase Hsp70 and Hsp90
levels. Unfortunately, there is a small therapeutic
window for the treatment of neurodegenerative dis-
eases with these molecules because cytotoxicity gen-
erally occurs at these concentrations. To circumvent
these issues, further development of Hsp90 inhibitors
for the treatment of neurodegenerative diseases
requires the identification of non-toxic inhibitors that
provide a large therapeutic window, but stimulate
the dissociation of HSF1 from Hsp90 at low concen-
trations and penetrate the blood–brain barrier
(BBB). A compound with s ch attributes could
potentially regulate the refolding of protein aggre-
gates, including tau, r initiate their degra ation
through the ubiquitin-proteasome pathway and pro-
vide an alternative approach toward the development
of drugs for these diseases.
Recently, an additional ATP-binding site on the
C-terminus of Hsp90 was elucidated and novobiocin
(Fig. 1) was identified as a competitive inhibitor of
ATP with low a"nity (!700 lM).15 Elucidation of
this new inhibitor and nucleotide-binding domain pro-
vided a novel opportunity to regulate the Hsp90-med-
iated protein folding machinery with small molecules.
In an e!ort to prepare more e"cacious inhibitors, a
small library of novobiocin analogues was prepared
and evaluated.16 A4 induced Hsp90 expression at con-
centrations significantly lower than those needed for
client protein degradation. Because of this finding,
we pr posed that A4 possessed u iqu properties that
could prove useful for the treatment of neurodegener-
ative disea es. In this article, we detail the neu pro-
tective e!ects of A4 and describe its potential
promise as a therapeutic lead compound for the treat-
ment of Alzheimer’s disease.
In order to prepare su"cient quantities of A4 for bio-
logical testing, it was necessary to devise an e"cient
synthetic route. As shown in Scheme 1, the coumarin
ring (2) was constructed by the condensation of
commercially available benzaldehyde 1 with glycine in
the presence of acetic anhydride.17 After selective
R = OMe, R' = H, GA
R = NHallyl, R' = H, 17-AAG
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Figure 1. Structures of Hsp90 inhibitors. Structures of the N-terminal
Hsp90 inhibitors, GA and 17-AAG, and the C-terminal inhibitors,
novobiocin and A4.
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 42 
requires Hsp70 for neuroprotection.  Chronic KU-32 treatment of mice deficient in the 
inducible form of Hsp70 did not reveal protection against streptozotocin (STZ)-induced 
diabetic peripheral neuropathy (DPN) while mice with inducible Hsp70 demonstrated 
protection against DPN upon KU-32 administration (Urban et al., 2010).  These studies 
support that C-terminal Hsp90 inhibitors modulate the heat shock response similarly to 
N-terminal Hsp90 inhibitors; however, the C-terminal inhibitors are much less toxic. 
As revealed in the preceding studies, C-terminal inhibitors are a promising 
potential agent for neurodegenerative disorders, but further studies are needed to 
demonstrate efficacy in models of AD.  The major focus of this dissertation is to 
examine the neuroprotective capabilities of KU-32 in cellular and animal models of AD.  
Our hypothesis is that KU-32 protects primary neurons from Aβ-induced death, as well 
as decreases hyperphosphorylated Tau in transgenic models of AD, and protects the 
mouse brains from neuronal loss and neuritic dystrophy.  We addressed the in vivo 
effect of KU-32 on only Tau phosphorylation as this pathological entity most closely 
correlates with the neurodegenerative phenotype (Spillantini et al., 1998). 
Overall, the studies performed here demonstrate that KU-32 is a potent 
neuroprotective agent in animal and cellular models of AD.  KU-32 decreases 
hyperphosphorylated Tau species and improves cognitive behavior in a transgenic 
mouse model of AD.  These experiments reveal that KU-32 is an efficacious compound 
for the treatment of AD as it improves cognition, decreases Tau pathology and can be 
tolerated at high doses for long periods of administration.  This drug may be a beneficial 
 
 43 
addition to the current treatments of AD and warrants further investigation into its 
therapeutic effects.  
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CHAPTER TWO: Novel C-Terminal Hsp90 Modulators are 
Neuroprotective in Cellular Models of Alzheimer’s Disease 
 
I.  Introduction 
Alzheimer’s disease (AD), like most age-related neurodegenerative disorders, is 
associated with the deposition of two pathological proteins; senile plaques (SPs) 
composed of β-amyloid peptides, and neurofibrillary tangles (NFTs) comprised of hyper-
phosphorylated Tau protein.   These aggregates lead to synaptic dysfunction, and 
ultimately to cognitive decline (Muchowski, 2002).  The manifestation of these misfolded 
aggregates in neurodegenerative disorders implies that the cellular machinery 
responsible for proper protein folding may become jeopardized as neurons age, 
therefore increasing the vulnerability of the brain to “proteotoxicity” (Spires et al., 2006, 
Peterson and Blagg, 2009).   
Recent studies have demonstrated that stimulation of the cellular protein quality 
control system, particularly the molecular chaperone family of heat shock proteins 
(HSPs), helps to prevent or protect against these misfolded toxic aggregates 
(Muchowski and Wacker, 2005a, Wilhelmus et al., 2007, Salminen et al., 2011).  This 
system consists of multiple protein complexes with Hsp90 as the major regulator 
(Peterson and Blagg, 2009).  Inhibitors of Hsp90 were originally developed as cancer 
therapeutics, but some compounds increase levels of molecular chaperones involved in 
protein re-folding or clearance such as Hsp70 and its co-chaperone Hsp40 (Fan et al., 
2003).   
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Previously identified compounds that inhibit the N-terminal ATPase of Hsp90, 
such as geldanamycin (GA), have been effective in providing protection against 
pathological aggregates in AD brain; however, these compounds have a small 
therapeutic window (Supko et al., 1995).  Therefore, our studies have focused on Hsp90 
inhibitors designed against the C-terminus of the protein, and are derivatives of the well-
characterized C-terminal Hsp90 inhibitor, novobiocin (Marcu et al., 2000a). 
A previous report from our lab identified a novel C-terminal Hsp90 inhibitor, A4, 
which demonstrated neuroprotective effects in vitro.  This compound did not decrease 
neuronal survival even at concentrations up to 10 µM, whereas GA caused ~80% death 
(Ansar et al., 2007).  Recently, we discovered a novel novobiocin analog, KU-32, that 
displayed greater potency in neuronal protection against Aβ toxicity (Figure 1.1).  The 
purpose of our studies was to characterize the neuroprotective effects of various 
novobiocin analogs, namely KU-32.  
 
II. Materials and Methods 
Preparation of primary neuronal cultures 
 Primary cortical neurons were prepared from day 18 embryonic rat fetuses 
(Harlan Sprague Dawley) as described previously (Michaelis et al., 1994, Michaelis et 
al., 1998, Michaelis et al., 2005).  All animal procedures were approved by the 
Institutional Animal Care and Use Committee (IACUC) in compliance with the 
regulations and standards of care and use of laboratory rodents as outlined by the 
National Institutes of Health.  After the final dissociation step, cells were re-suspended 
in DMEM/F12 medium (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal 
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bovine serum (Atlanta Biologicals, Lawrenceville, GA).  Neurons were plated at a 
density of 250,000 cells per 35mm2 glass-bottom dishes (Mat-Tek Co., Ashland, MA) 
coated with 10 µg/mL poly-D-lysine (PDL) and 5 µg/mL laminin.  Twenty-four hours after 
initial plating, the serum-containing medium was removed and replaced with Neurobasal 
medium containing 2% B-27 supplements (Invitrogen, Carlsbad, CA).  Cells were grown 
at 37°C in 5% CO2 and 97% humidity.  
 
Aβ peptide preparation and cell culture treatments 
 The Aβ peptides were purchased from Anaspec (Fremont, CA). The Aβ1-42 and 
Aβ25-35 peptides were dissolved in 50mM Tris-HCL pH 7.4 and aliquots stored at -80°C.  
Prior to adding these peptides to the tissue culture medium, they were incubated at 
37°C for 24 hours to allow them to oligomerize.  
 Primary neurons were allowed to grow 7 days in vitro (DIV7) before any 
treatments.  Cultures were pretreated for 2 hours with vehicle (5% Captisol®) or a 
novobiocin derivative (KU-32, KU426, KU-430, and KU-433) dissolved in 5% Captisol® 
followed by the addition of 10 or 25 µM Aβ peptides and incubated for 48 or 96 hours as 
indicated in the figures.  In a separate experiment, following pre-treatment for 2 hours 
with the novobiocin derivatives, 200 nM thapsigargin (Tg), an inhibitor of the sarco-ER-
calcium-ATPase (SERCA), was added for 20 or 24 hours as noted in the figure legend.  
Additional experiments were performed with KU-426, KU-430, and KU-433 in which 
each compound was incubated for 2 hours before the addition of 25 nM Okadaic Acid 
(OA), a protein phosphatase 2A inhibitor, for 24 hours. 
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Measurement of cell viability 
After treatments, the Live-Dead assay was performed as previously described 
(Michaelis et al., 1998, Michaelis et al., 2005).  Briefly, 20 µM propidium iodide and 150 
nM calcein acetoxy-methylester (Invitrogen, Carlsbad, CA) were added to label the live 
neurons with green fluorescence and dead neurons with red.  Images were captured 
from 8 fields per dish, and the number of dead and viable cells counted.  The percent of 
live cells was calculated in each dish.  All experiments were completed from 3 neuronal 
preparations, with ~1,000 cells assessed per treatment condition.  Data were graphed 
as the percent viable cells calculated from the total number of neurons counted per 
treatment condition (SigmaPlot 11).  Significant differences between treated and control 
cells were determined using Student’s t-test.  One-way ANOVA analysis with a 
Bonferroni post-hoc test was used to determine statistical significant between treated 
groups as demonstrated in the figure legend. 
 
Transfection of neuroblastoma cells 
The neuroblastoma SH-SY5Y cell line (ATCC, Monasses, VA) was used for 
studies with transfected mutant Tau.  The cells were grown on 100 mm2 dishes with 15 
mL of DMEM/F12 medium (Sigma-Aldrich, St. Louis, MO) supplemented with 10% fetal 
bovine serum (Atlanta Biologicals, Lawrenceville, GA).  When the SY5Y cells reached 
90-95% confluency, wild type and mutant P301L Tau isoforms without exons 2 or 3, but 
with exon 10 (-2-3 P301L and -2-3 Tau4 DNA plasmids; gifts from Dr. Mike Hutton, Eli 
Lilly Co.), were prepared for transfecting the cells.  Initially the cells were diluted in 1.5 
mL of Opti-MEM I Reduced Serum medium (Invitrogen, Carlsbad, CA), termed Mixture 
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1.  A second mixture, Mixture 2, of Lipofectamine 2000 diluted in the appropriate Opti-
MEM I medium was prepared with a final ratio of 1:3 (DNA (µg): Lipofectamine 2000 
(µL)), and the mixture was incubated ~25 minutes at room temperature.  After the 25-
minute incubation, Mixture 1 and Mixture 2 were combined and permitted to incubate for 
20 minutes at room temperature.  Finally, the DNA/Lipofectamine 2000 mixture complex 
was added to 100 mm2 dishes of the SY5Y cells.  These cells were placed in the 
incubator at 37°C in 5% CO2 and 97% humidity for about 6 hours.  The medium was 
replaced with 0.2 mg/mL of the selection compound G418 (Sigma-Aldrich, St. Louis, 
MO) in DMEM/F12 medium with 10% fetal bovine serum.  The DNA transfection 
plasmids contain a neomycin resistant gene, allowing them to grow in the presence of 
G418; therefore the non-transfected cells die leaving only transfected cells growing.  In 
order to produce a stably transfected cell line, twenty-four hours post-transfection, the 
concentration of G418 in the medium was increased to 0.5 mg/mL.  The cells remained 
growing in this concentration of G418 to maintain the stable transfection.   
 
Verification of successful transfection 
 PCR analysis 
The SY5Y, wild type Tau and P301L Tau-transfected cells were genotyped using 
reverse transcription-PCR-amplification.  Purified plasmids for the wild type Tau and 
P301L Tau transfectants were used a positive control.  For the presence of the 
pcDNA3.1 vector, the following primers were used: forward primer, PCDNAF, 5’-
CTAGAGAACCCACTGCTTACTG-3’; reverse primer, TauAmR, 5’-
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CAGGGAGGCAGACACCTC-3’.  A 1300 bp band indicated the presence of the vector, 
as well as a successful transfection.     
  
 Immunoblot analysis 
The SY5Y, wild type Tau, and P301L Tau transfectants were washed twice in 
phosphate buffered saline (PBS), lysed in kinase lysis buffer (20 mM Tris-HCl pH 7.4, 
140 mM NaCl, 1 mM PMSF, 1 mM sodium orthovanadate, 10 mM NaF, 0.1% Nonidet-
40, 1 mM EDTA, 26 uM ALLN, protease inhibitors cocktail set III (Calbiochem), and 
phosphatase inhibitors cocktail III (Sigma)), and collected by scraping the dishes, 
recovering, and homogenizing all contents.  The protein concentration was determined 
using the bicinchoninic acid assay (BCA) from Thermo Fisher Scientific.  Reducing 
sample buffer (50mM Tris-HCl at pH 6.8, 6.7% glycerol, 2.7% SDS, 0.05% 
Bromophenol Blue, and 250 mM dithiothreitol) was added to 25 µg aliquots of each 
sample and resolved by SDS-PAGE.  The proteins were transferred to polyvinylidene 
fluoride (PVDF) membrane as described previously (Zaidi and Michaelis, 1999).  The 
membrane was probed with: PHF-1, an antibody that recognizes pS396/404 
hyperphosphorylated Tau; Tau5, an antibody for total Tau; and Actin, which served as a 
loading control.  Immunoreactive proteins were detected using chemiluminescence.  All 
primary incubations were completed on the same membrane using One Minute 
Stripping Buffer (GM Biosciences) to remove the previous antibody reaction.   
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Lactate dehydrogenase assay for necrotic cell death 
 The SY5Y and transfected cells were plated at a density of 400,000 cells per well 
in a 48-well plate.  Twenty-four hours after plating, the cells were differentiated by 
placing the cells in serum-free medium (Schubert et al., 1969, Seeds et al., 1970, 
Evangelopoulos et al., 2005).  The cells were differentiated for 24 hours and were 
treated with 100 nM KU-32 or 5% Captisol®.  Two, 4, 6, and 12 hours post-treatment 
the LDH assay was performed by measuring release of LDH into the medium as an 
indication of the loss of cell membrane integrity. The LDH activity was determined by 
removing the medium, and centrifuging it at 1,000 rpm for 30 seconds. Each sample 
was placed into 3 wells on a 96-well plate.  Fresh medium was used as the blank, and 
medium from cells treated with 1% Triton-X 100, which releases all the LDH, was used 
as an indicator for maximal loss of membrane integrity.  To measure LDH in the 
medium, the substrate/enzyme solution (1.2 mM INT, 104 mM L-Lactate, 20 mM NAD+ 
(all from Sigma-Aldrich, St. Louis, MO), Diaphorase (Worthington, Lakewood, NJ), and 
0.2M Tris, (pH 8.6) was added to each well and the mixture incubated at room 
temperature in the dark for 30 minutes.  The stop solution (6% acetic acid/0.5% Triton-X 
100) was added, and the plate was read at 490 nm.  Results were graphed as percent 
cell death (SigmaPlot 11).  All treatments were performed in triplicate. 
  
MTT assay for succinate dehydrogenase 
 The SY5Y cells, -2-3 Tau4, and -2-3 P301L-transfected cells were grown at a 
density of 500,000 cells per 35-mm2-dish.  Twenty-four hours after plating, the cells were 
differentiated in non-serum containing medium.  Differentiation was allowed to proceed 
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for 24 hours (Schubert et al., 1969, Seeds et al., 1970, Evangelopoulos et al., 2005), 
and then the cells were treated with either 100 nM KU-32 or 5% Captisol for 2, 4, and 6 
hours.   After the indicated treatments, the medium was aspirated.  The cells were 
washed once with warm non-phenol red-containing medium, and 1.5 mL of the assay 
solution (1 to 10 dilution of 5 mg/mL MTT in non-phenol red containing medium) was 
added.  The cells were placed at 37°C for 1 to 3 hours to allow crystal formation.  After 
crystals formed, the assay solution was aspirated and replaced with 1 mL solvent (0.4 M 
HCl in absolute isopropanol).  The mixture was triturated to dissolve crystals completely, 
transferred to Eppendorf tubes, and centrifuged at 13,000 rpm for 2 minutes.  The 
samples were read at 570 nm (and 650 nm for background subtraction).  Results were 
normalized to no treatment and graphed as percent cell death.  Each treatment 
condition was repeated 6 times, and the statistical significance between treatment 
groups was determined using Student’s t-test.   
 
III. Results 
KU-32 protection against various toxic agents in primary neuronal culture 
 In AD brain, Aβ oligomers are believed to lead to synaptic loss and neuronal cell 
death.  The death of the neuron is often due to calcium dysregulation as a result of 
various types of stress (Seyb et al., 2006, Zempel et al., 2010).  In our study, we used 
two different ways to increase intraneuronal calcium levels: either Aβ1-42, Aβ25-35 
peptides or Tg, an inhibitor of the sarco-ER calcium-ATPase (SERCA).  Our goal was to 
determine if KU-32 protects against these toxic compounds in a fashion similar to the 
previously identified novobiocin derivative, A4 (Ansar et al., 2007).  Primary cortical 
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neurons were treated with varying doses of KU-32 ranging from 1 nM to 100 nM 
dissolved in 5% Captisol®.  Primary neurons were pre-treated for 2 hours before Aβ 
peptides or Tg was added.  Live-Dead assays were performed to test cell viability.  
Figure 2.1 demonstrates that KU-32 is protective against Aβ1-42, Aβ25-35 and Tg in a 
dose dependent fashion with an estimated EC50 ~ 0.1nM.  
 
Figure 2.1: Dose dependent protection exhibited by KU-32 against Aβ peptides 
and Tg.  Primary cortical neurons were pre-treated for 2 hours with the indicated doses 
of KU-32 dissolved in 5% Captisol® (vehicle) followed by incubation in (A) 10 µM Aβ1-42, 
(B) 10 µM Aβ25-35, or (C) 200nM Tg.  The Aβ peptides were incubated with cells for 48 
hours and Tg was present for 24 hours.  The Live-Dead assay was used to determine 
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percent survival.  All experiments were completed in triplicate.  Statistical analyses were 
completed using a one-way ANOVA with Bonferroni.   * p <0.05. 
 
Analogs of KU-32 provide differential protection against various toxic agents 
 The synthesis for KU-32 is a lengthy, multi-step process.  In an effort to decrease 
the synthesis time, analogs were produced that require fewer steps for production.  We 
tested these analogs in the Live-Dead assay to see if any provided similar protection as 
KU-32.  We used 100 nM concentrations and pre-treated primary cortical neurons for 2 
hours prior to stimulation with the toxic Aβ peptides, Tg and the protein phosphatase 2A 
(PP2A) inhibitior, okadaic acid (OA).  As shown in Figure 2.2, the analog KU-426 
provided significant protection against Tg- and Aβ1-42-induced cell death.  However, 
unlike KU-32, KU-426 did not provide statistically significant protection against Aβ25-35 
toxicity (Figure 2.2).  A second novobiocin derivative, KU-430 significantly protected 
neurons against the two Aβ peptides and Tg-induced toxicity (Figure 2.3), similarly to 
KU-32.  A third novobiocin analog, KU-433, was significantly protective against Tg only 
(Figure 2.4).  Surprisingly, KU-433 did not significantly protect against the Aβ peptides, 
and was less like KU-32 than the other test novobiocin derivatives.  Interestingly, none 
of the compounds were able to protect against OA.  Overall, these results reveal that 
the derivative KU-430 provided the best protection against the same toxic agents as 
KU-32.   
It should be noted that the no treatment groups used in the novel drug treatment 
studies had lower survival than those in the dose response studies (Figures 2.2-2.5) 
completed with only KU-32 (Figure 2.1).  In the KU-32 dose dependent protection 
studies, the no treatment group displayed about 90% to 95% survival while the novel 
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novobiocin derivative studies showed about 55% to 60% survival.  These differences in 
survival can be attributed to poorly optimized culture conditions.  Also, as a result of the 
lowered survivability of the cell preparations used for the novobiocin derivative studies, 
these cell populations were less susceptible to 10 µM Aβ25-35 treatments.  Therefore, we 
increased the concentration to 25 µM Aβ25-35 in order to test for statistically significant 
toxicity in these neuronal cultures.      
 
Figure 2.2: KU-426, a protective analog of KU-32.  Primary cortical neurons were pre-
treated with 100 nM of KU-426 dissolved in 5% Captisol® (vehicle) for 2 hours before 
incubation in 200 nM Tg for 20 hours, 25 nM OA for 24 hours, 25 µM Aβ25-35 or 10 µM 
Aβ1-42 for 96 hours.  The Live-Dead assay was used to determine percent survival.  
Experiments were completed in triplicate.  p values are indicated on graph. 
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Figure 2.3: KU-430 a neuroprotective novobiocin derivative similar to KU-32.  
Primary cortical neurons were pre-treated with 100 nM of KU-430 dissolved in 5% 
Captisol® (vehicle) for 2 hours before incubation in 200 nM Tg for 20 hours, 25 nM OA 
for 24 hours, 25 µM Aβ25-35 or 10 µM Aβ1-42 for 96 hours.  The Live-Dead assay was 
used to determine percent survival.  Experiments were completed in triplicate.  p values 
are indicated on graph. 
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Figure 2.4: KU-433, an analog of KU-32.  Primary cortical neurons were pre-treated 
with 100 nM of KU-433 dissolved in 5% Captisol® (vehicle) for 2 hours before 
incubation in 200 nM Tg for 20 hours, 25 nM OA for 24 hours, 25 µM Aβ25-35 or 10 µM 
Aβ1-42 for 96 hours.  The Live-Dead assay was used to determine percent survival.  
Experiments were completed in triplicate.  p values are indicated on graph. 
  
KU-430 provides similar protection to KU-32 in primary cortical culture 
 Since the analog KU-430 (Figure 2.3) demonstrated the best protection against 
toxic species in the Live-Dead assay, we wanted to determine if KU-430 and KU-32 
provide a similar level of protection.  Using the Live-Dead assay, we pre-treated primary 
cortical neurons with 100 nM KU-32 or KU-430 then treated with 25 µM Aβ25-35 or 10 µM 
Aβ1-42 for 96 hours.  The results indicate that 100 nM pre-treatment with KU-430 offered 
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similar protection against Aβ25-35; however, KU-32 provided ~10% better protection 
against Aβ1-42 at the same concentration although this difference is not statistically 
significant (p=0.112) (Figure 2.5).  These data suggest that KU-430 is about as 
protective as KU-32 in shielding against amyloid-β toxicity.   
 
Figure 2.5: Neuronal protection of KU-32 and KU-430. Primary cortical neurons were 
pre-treated with 100 nM of KU-430 or KU-32 dissolved in 5% Captisol® (vehicle) for 2 
hours before incubation in 25 µM Aβ25-35 or 10 µM Aβ1-42 for 96 hours.  The Live-Dead 
assay was used to determine percent survival.  Experiments were completed in 
triplicate.  Statistical analysis was completed using a one-way ANOVA with Bonferroni.  
* p <0.05.   
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KU-32 treatment against toxicity of stable P301L Tau mutation in SY5Y cells  
In order to determine if KU-32 could protect against an inherent genetic mutation 
leading to aggregated Tau protein formation, we transfected the immortalized human 
neuroblastoma cell line, SH-SY5Y, with mutant P301L Tau. This mutation leads to 
increases in hyper-phosphorylated Tau as observed in neurofibrillary tangles (NFTs) in 
AD brain.  We used two different plasmids.  One contained normal human Tau, which 
served as a control for Tau overexpression, and the other expressed mutated human 
Tau: -2-3 Tau4 and -2-3 P301L.  The Tau protein is essential in maintaining the axonal 
integrity of neurons.  In disease states, like AD, it becomes hyperphosphorylated and 
dissociates from the axons leading to axonal deterioration and NFT formation. Missense 
mutations within Tau, like P301L, V337M and R406W, hasten the formation of Tau 
fibrils (Nacharaju et al., 1999).  Normal human Tau exists in six different isoforms as a 
result of alternative splicing.  Tau contains 16 exons, of which 8 are alternatively 
spliced. These include exons 2, 3, 4A, 6, 8, 10, 13, and 14 (Goedert et al., 1989a, 
Goedert et al., 1989b, Himmler, 1989, Wei and Andreadis, 1998, Gao et al., 2000).  The 
plasmids used in our studies did not contain exons 2 or 3, but they did contain exon 10, 
which resides within the microtubule-binding domain.  The P301L mutation found in 
exon 10 accelerates fibril formation (Nacharaju et al., 1999), while the presence or 
absence of exons 2 and 3 have no effect on microtubule binding (Binder et al., 1985).  
The stable transfection was performed and confirmed by PCR and immunoblotting 
(Figure 2.6).  The PCR results revealed a 1319 base pair long sequence that was not 
amplified in the non-transfected SY5Y cells.  A successful transfection was also 
demonstrated by the immunoblots.  The PHF-1 labeling, which recognizes paired helical 
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filament formation as a result of hyperphosphorylated Tau, demonstrated higher levels 
of immunoreactivity in the transfected cells.  These results were expected as mutant 
P301L Tau leads to fibril formation, and it has also been demonstrated that 
overexpression of wild type human Tau can lead to increases in hyperphosphorylated 
Tau (Andorfer et al., 2003).  The second immunoblot labeled with Tau5, which 
recognizes phosphorylated and non-phosphorylated forms of Tau, revealed that the 
transfectants had higher levels of total Tau in comparison to the SY5Y cells.  These 
results were expected since wild type and mutant P301L Tau were added to these cells. 
                         
Figure 2.6: PCR and immunoblots of Tau transfection in SY5Y cells.  (A) PCR was 
performed to amplify a 1319 bp fragment present only in transfected cells.   M= marker, 
1=SY5Y cells, 2=Tau4 transfected cells, 3=P301L transfected cells, 4=Tau4 plasmid, 
and 5=P301L plasmid.  (B) Immunoblotting of transfected cells with antibodies 
recognizing Tau fibrils (PHF-1), total Tau (Tau5) and the loading control (Actin) 
1=SY5Y, 2=Tau4 transfected cells, and 3=P301L transfected cells. 
 
Before looking for KU-32 protection against mutant P301L-induced death in the 
SY5Y cells, we first had to see if the presence of the mutant Tau potentiated cell death. 
LDH release was assessed at 0, 12, 24, and 30 hours after non-serum containing 
medium was added for differentiation.  The assay demonstrates that cells containing the 
P301L mutation exhibited about 12% more cell death starting at 12 hours post 
differentiation and sustained a greater level of cell death until 30 hours post 
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differentiation than the wild type Tau transfectants and SY5Y cells (Figure 2.7).  The 
increase in cell death by the P301L mutation was relatively small; however, it was 
statistically significant. 
 
Figure 2.7: LDH measurement of cell death in transfected cells.  Transfected and 
non-transfected SY5Y cells were grown in the presence of serum-free medium for the 
indicated times.  LDH assays were performed in triplicate to determine percent death. 
*p<0.001 for SY5Y vs. P301L cells. 
 
After confirming an increase in necrosis with the presence of the P301L mutation, 
we tested if KU-32 could protect the cells against this genetic mutation that increased 
cell death.  Twenty-four hours post differentiation, the transfected cells were treated with 
100nM KU-32 or 5% Captisol® for 2, 4, 6, and 12 hours.  The LDH results revealed that 
KU-32 did not protect cells against necrotic death (Figure 2.8).  Surprisingly, KU-32 
enhanced cell death in the P301L transfected cells.  
Since the LDH assay is a measure of necrosis and KU-32 did not show 
protection of the mutant cells, we hypothesized that the P301L mutation was possibly 
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inducing another route of cell death like apoptosis.  The MTT assay measures apoptotic 
as well as necrotic cell death; so we used this assay to assess protection with KU-32 in 
the stable transfectants.  The results in Figure 2.9 demonstrated that KU-32 did not 
protect against apoptotic cell death in these cells (Figure 2.9).  Similarly, the MTT 
results indicated that KU-32 significantly increased cell death in both the P301L and 
wild-type Tau4 transfected cells. 
 
Figure 2.8: Effect of KU-32 treatment in transfected cells as monitored by LDH 
release. Transfected cells were grown in 48-well plate for 24 hours and then 
differentiated in non-serum containing medium for 24 hours.  100 nM KU-32 or 5% 
Captisol® was applied to the cell culture medium and LDH assays were performed at 
the indicated times after treatment.  Percent cell death in (A) P301L transfected cells 
and (B) wild-type Tau4 transfected cells was graphed. 
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Figure 2.9: Effect of KU-32 in transfected cells as determined by MTT assay.  
Transfected cells were grown in 35 mm2 dishes for 24 hours and then differentiated in 
non-serum containing medium for 24 hours.  100 nM KU-32 or 5% Captisol® was given 
to the cell culture medium and MTT assays were performed at the indicated times after 
treatment.  The data from (A) P301L transfected cells and (B) wild-type Tau4 
transfected cells were graphed as percent cell death against no treatment.  
 
IV. Discussion 
Previous studies in the Michaelis lab have demonstrated that the novobiocin 
derivative, A4, protects against Aβ-induced cell death (Ansar et al., 2007). Our 
observations with the A4 analog, KU-32, are consistent with the previously published 
results, indicating that KU-32 protects against Aβ-induced cell death as well as Tg 
toxicity in primary rat neurons (Figure 2.1). The other novobiocin derivatives: KU-426, 
KU-430, and KU-433 (Figures 2.2-2.4), further substantiate the neuroprotective qualities 
of these novel C-terminal Hsp90 modulator analogs.  However, these analogs led to 
differential protection, and KU-430 was the only analog that provided protection similar 
to that seen with KU-32 (Figure 2.5).  Other studies involving KU-32, KU-430, and KU-
433 have demonstrated protection against in vitro glucose toxicity (Kusuma et al., 
2012).  KU-32 has also revealed protection against neuregulin-induced demyelination in 
primary rat sensory neurons (Urban et al., 2010).  Previous reports also demonstrate 
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that KU-32 protects against Aβ-induced toxicity in differentiated and non-differentiated 
neuroblastoma cells (Lu et al., 2008).   
Previous studies with other Hsp90 inhibitors further demonstrate protective 
properties of these compounds in models of AD.  Greengard’s group demonstrated that 
GA provided protection in AD models by decreasing phosphorylated Tau in COS-1 cells 
(Dou et al., 2003), and his group later revealed that a novel N-terminal Hsp90 inhibitor 
developed in their lab was protective by apparently decreasing phosphorylated Tau in 
both COS-7 cells and the JNPL3 AD mouse model (Luo et al., 2007).  Greengard’s 
studies suggest that the N-terminal Hsp90 inhibitors are initiating proper folding of the 
phospho-Tau aggregates.  Dickey and colleagues developed a novel Hsp90 inhibitor 
that demonstrated neuroprotection through decreases in phosphorylated Tau in HeLa 
cells that overexpress Tau, as well as lowered levels of phosphorylated Tau, in a mouse 
model of Tauopathy by targeting clearance of p-Tau through the proteasome (Dickey et 
al., 2007).  The inhibitors Dickey and Greengard’s groups developed were directed to 
the N-terminal portion of Hsp90 while KU-32 acts at the C-terminal end of Hsp90 (Matts 
et al., 2011). 
 Our in vitro cell model expressing the mutant P301L Tau did not demonstrate 
decreases in necrotic (Figure 2.8) or apoptotic death (Figure 2.9) with KU-32 treatment.  
Our transfection produced the appropriate phenotype as shown in Figure 2.6.  The 
SY5Y cells transfected with wild-type Tau, which was used as a control for Tau 
overexpression, and mutant P301L Tau both demonstrated increases in PHF-1, an 
early marker of Tau fibrillization and hyperphosphorylation (Reed et al., 1997, Reed et 
al., 1998).  Both of the transfectants also showed increases in total Tau levels, as 
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should be expected in comparison to SY5Y cells. It is possible that we did not observe 
protection in the P301L transfected cells because of low Hsp70 levels.  The SY5Y cell 
line, with or without the presence of the transfectants, has low levels of Hsp70 protein 
(Myung et al., 2004).  Previous reports demonstrated that Hsp70 is required for KU-32 
neuroprotection (Urban et al., 2010).  Thus, it is possible KU-32 did not prevent cell 
death in the mutant transfectants because they lack sufficient induction of Hsp70 by KU-
32 that would theoretically lead to the refolding of the Tau fibrils.  
As AD treatment efforts progress, the focus of treatment development has shifted 
from disease pathology to neuroprotection.  As many clinical trials have failed in their 
development of drugs targeting the pathology of AD, it has been hypothesized that 
previously developed therapeutic treatments have been directed at the wrong problem 
(Golde et al., 2011).  Instead of trying to ameliorate the pathological problems 
associated with the disease markers such as senile plaques and Tau tangles, we 
should focus our efforts in providing neuroprotection.  Improvements in cognitive 
function have been demonstrated even in the presence of Tau aggregates, as revealed 
in a study by SantaCruz and colleagues.  Using the tet-off rTg4510 mouse model, 
where the presence of doxycycline prevents the development of mutant P301L Tau 
aggregates, the group administered doxycycline to 2.5-month old mice that had 
developed NFT pathology.  At 4.5 months, the group performed behavioral analysis 
using the Morris water maze to demonstrate that the mice were able to improve 
cognition in the presence of hyperphosphorylated Tau aggregates when the 
development of new Tau aggregates was prevented (SantaCruz et al., 2005).  
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Consequently, this study reveals that clearing Tau pathology may not be necessary for 
functional improvements.   
As AD develops in humans, not every cell has the abnormal aggregates.  
However, even though neurons are post-mitotic, Liu and colleagues have demonstrated 
that pathological Tau is transferred to nearby or susceptible neurons through synaptic 
transmission (Liu et al., 2012).  Therefore, it is important to capitalize on the properties 
of a given cell to clear faulty proteins quickly and prevent the passage of aggregates to 
new cells.  This suggests that we should center our efforts on enhancing cellular 
functions in the presence of the pathological entities as opposed to trying to remove 
them.  Therefore, our discovery of a neuroprotective novel compound to promote the 
protein folding machinery is in line with the current shift in AD research, where the focus 
is now centered on neuroprotective agents that may indeed be disease-modifying 
agents.  
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CHAPTER THREE: KU-32 is Neuroprotective in Mouse Models of AD   
 
I.  Introduction  
Typically Tau is associated with microtubules, and functions in the support of 
axonal structure and neuronal development (Weingarten et al., 1975).  Tau dissociates 
from the microtubules when it is hyperphosphorylated and this leads to pathological Tau 
aggregates called neurofibrillary tangles (NFTs) (Grundke-Iqbal et al., 1986, Kosik et al., 
1986).  Diseases characterized by aggregated Tau include Alzheimer’s disease (AD), 
frontotemporal dementia with parkinsonism linked to chromosome 17 (FTDP-17), and 
Pick’s disease (Dickson, 1997).  Of the ‘Tauopathies,’ AD is associated with two protein 
aggregates: amyloid-β and Tau; however, it is Tau aggregation that most closely 
correlates with loss of neurons (Gomez-Isla et al., 1997) and dementia (Ihara et al., 
1986, Crystal et al., 1988).  Several studies have demonstrated that mutations in the 
Tau gene lead to various diseases known as ‘Tauopathies,’ the most common of which 
is FTDP- 17.  These studies were the first to prove that abnormalities in Tau alone 
directly lead to neurodegeneration (Hutton et al., 1998, Spillantini et al., 1998).  
Nevertheless, the signaling events that lead to sporadic NFT formation, as seen in AD 
brain, are still widely debated.  
In order to investigate the different signaling events that lead to NFT formation in 
AD, studies require that mouse models express mutated Tau in order for them to 
develop the characteristic protein aggregates associated with the disease.  Some 
models only generate aggregates of Aβ peptides, which contain mutations in the 
amyloid precursor protein (APP) and/or the Presenilins (Chapman et al., 1999, 
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Gureviciene et al., 2004).  Other models are designed to develop the neurofibrillary 
pathology associated with AD through the use of mutated Tau gene.  Most of these 
mouse models overexpress the P301L mutation found within the microtubule-binding 
motif of Tau.  The Tau becomes hyperphosphorylated, eventually leading to formation 
of Tau aggregates within mouse brains (Lewis et al., 2000).  There is also one model 
that contains both Aβ plaques and neurofibrillary pathology, and is called the 3xTg 
mouse model.  This model has three mutations: one in APP; one in presenilin; and one 
in Tau (Oddo et al., 2003).   
In this chapter, two different mouse models that express mutant Tau tangles 
were used to investigate the effect of the novel C-terminal inhibitor, KU-32 on Tau fibrils 
and their consequences.  The first mouse model was provided by Dr. Jada Lewis and 
called JNPL3.  This model contains the human P301L transgene under the control of 
the mouse prion promoter (MoPrP).  The mouse develops Tau pathology predominately 
in the spinal cord and cortical region of the brain, with limited NFT formation in the 
hippocampus.  Unfortunately, JNPL3 mice develop motor defects, which are correlated 
with degeneration of motor neurons, and thus become impaired in walking.  There is 
little brain neurodegeneration in the JNPL3 mouse model, as opposed to human AD, 
which is associated with significant neurodegeneration (Lewis et al., 2000). 
The second mutant Tau mouse model we used was the rTg4510.  These mice 
contain the human P301L transgene, but unlike the JNPL3 mice, P301L expression is 
driven by the CamKII promoter containing a tet-off cassette.  CamKII drives production 
of high expression of the P301L mutant Tau in the cortical and hippocampal regions of 
the brain, which is similar to human AD (Spires et al., 2006).  In comparison to the 
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JNPL3 mice, the rTg4510 mice have 17-fold higher expression of P301L Tau in the 
absence of doxycycline, and, importantly, the rTg4510 mice develop classic 
neurodegeneration much like that observed in human AD (Berger et al., 2007).  
In Chapter Two of this dissertation, we demonstrated significant protection with a 
novel C-terminal Hsp90 modulator, KU-32, in primary neuronal cultures subjected to 
various cellular toxins i.e. Aβ peptides and Thapsigargin (Tg). The purpose of the 
studies in this chapter was to determine if KU-32 could lead to neuroprotective effects in 
vivo.  Previous studies using blood brain barrier (BBB) permeable N-terminal Hsp90 
inhibitors showed decreases in hyperphosphorylated Tau in mouse models of 
Tauopathy using immunohistochemical and Western blotting analysis (Dou et al., 2003, 
Dickey et al., 2007, Luo et al., 2007).  Our novel compound, KU-32, demonstrates BBB 
permeability, and does not exhibit toxic effects at concentrations required to test 
properties of the drug (unpublished results).  We hypothesized that our novel C-terminal 
Hsp90 modulator, KU-32, would act similarly to the N-terminal Hsp90 inhibitors and 
significantly decrease hyperphosphorylated Tau in the two P301L transgenic mouse 
models, as well as restore and/or protect against neuronal damage. 
 
II.  Materials and Methods 
Mutant Tau mouse models and exposure to KU-32 
JNPL3 mice 
A Tau mutant mouse model was developed as described in Nature 
Genetics by Lewis et al. (Lewis et al., 2000), and heterozygous breeder mice 
were given to the Michaelis lab by Dr. Jada Lewis. 
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In order to examine the effect of KU-32 treatments, two to four month old 
JNPL3 or C57BL/6 (wild type control) mice were treated intraperitoneally with 20 
mg/kg of KU-32 or vehicle (12.5% Captisol®), five times a week, for six months. 
Seven JNPL3 mice were treated with 20 mg/kg, and ten JNPL3 mice were 
treated with the vehicle.  Four wild type mice were used, two of which were 
treated with 20 mg/kg of KU-32 and two treated with vehicle. 
  
 rTg4510 mice 
Heterozygous inducible Tau responder mice containing a tetracycline-
operon-responsive (TRE) system upstream from the P301L transgene and 
heterozygous CamKIIa activator mice with a tet-off open reading frame 
downstream of the promoter, where activation of P301L gene expression occurs 
upon removal of doxycycline, were received from the Neuroscience Department, 
Mayo Clinic, Jacksonville, FL (Ramsden et al., 2005, SantaCruz et al., 2005).  To 
create the colony, four lines of mouse were required.  The Tau responders were 
bred and maintained onto an FVB/N mouse background, while the CamKIIa 
activator mice were bred and maintained onto the SVJ129S6 model.  All progeny 
from each litter were genotyped.  Only mice containing the responder sequences 
were bred with mice expressing the activator sequences to obtain the F1 hybrid 
rTg4510 mice that were used in these studies.  FVB mice were used as wild-type 
controls.   
To test the effects of KU-32 on Tau phosphorylation and 
neurodegeneration, 2.5-month old mice were put on a treatment regimen with 
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intraperintoneal (i.p.) injections of vehicle (5% Captisol®) or KU-32. Eight 
rTg4510 mice were injected 2 times per week with 60 mg/kg of KU-32 for a 
period of 10 weeks.  Eight rTg4510 mice received only the 5% Captisol® vehicle 
on the same schedule.  Four non-transgenic littermates served as the controls, 2 
treated with KU-32 and 2 treated with 5% Captisol®.   
 
Analysis of brain sections of treated mice 
Immunohistochemical labeling of Tau in JNPL3 mutant mice 
After 6 months of KU-32 treatment, brains were recovered from 8 to 10 
month old mice.  Hemibrains were fixed in 4% paraformaldehyde, submerged in 
30% sucrose for 7 days, flash frozen in 4-methyl-butane in liquid N2, and cut on a 
cryostat.  Free-floating sections were cut at 20 µm and stored at 4°C in 1xPBS.  
Sections were placed in 12-well plates, and permeabilized with 0.1% Triton-X 
100 for 30 minutes, rinsed 2 times in 1xPBS and incubated for 30 minutes in 1% 
hydrogen peroxide in 50% methanol with 0.1% sodium azide to block 
endogenous peroxidase activity.  The slides were rinsed 2 times with 1xPBS and 
then incubated in 2% gelatin for 1 hour at 37°C to further block endogenous 
antibody binding.  Primary antibodies directed against phospho-specific Tau 
epitopes, CP13, which recognizes pS202 (a gift from Dr. Peter Davies) and AT8, 
which recognizes pS202/T205 (Pierce Endogen, Rockford, IL) were incubated 
overnight at 4°C.  A Vectastain kit, standard streptavidin-peroxidase labeling 
against mouse antibodies was used to visualize antibody labeled proteins with 
DAB as the chromagen (Vector, Burlingame, CA).  Sections were viewed with the 
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Nikon Eclipse 80i microscope and images were captured at 40x magnification 
with a Photometrics CoolSnap camera. Positive labeling was quantified using 
Metamorph.  Data were analyzed for statistical significance using Student’s t test 
(SigmaPlot 11).    
 
Immunofluorescent labeling of brain sections in rTg4510 Tau mutant mice 
Following 10 weeks of KU-32 administration, the mice were sacrificed, the 
brains excised, and the cerebella removed.  The brains were fixed in 4% 
paraformaldehyde.  Hemibrains were submerged in 30% sucrose for 7 days, 
flash frozen in 4-methyl butane in liquid N2, and cut on a cryostat.  Free-floating 
sections were cut at 20 µm and stored at 4°C in 1xPhosphate-buffered saline 
(PBS).  Sections were transferred to 12-well plates and incubated in 2% gelatin 
for 1 hour at 37°C to block endogenous fluorescence, rinsed 3 times with 1x 
PBS, and incubated for 15 min with 1 mg/mL sodium borohydride to further 
reduce background fluorescence.  Sections were rinsed 3 times in 1xPBS and 
incubated for 15 minutes with 0.01% Triton-X 100 at room temperature, and 
rinsed 3 times in 1xPBS.  The following primary antibodies were used to label the 
sections: microtubule-associated protein 2 (MAP2) (1:250), Synaptophysin 
(1:500), and neuronal nuclei (NeuN) (1:500), all from Millipore (Bellerica, MA) as 
well as CP13 (1:100) antibodies against phosphorylated S202 of Tau.  The 
sections were incubated with the specific primary antibodies at 4°C overnight.   
The next day, sections were rinsed 3 times with 1xPBS and incubated with 
goat anti-mouse AlexaFluor 488 (1:1000) and/or goat anti rabbit AlexaFluor 568 
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(1:1000), both from Invitrogen (Carlsbad, CA), for 2 hours at 37°C.  The antibody-
labeled sections were transferred to microscope slides, viewed with an 
Olympus/3I spinning disk confocal/epifluorescence/TIRF inverted microscope, 
and images were captured at 40x magnification with SlideBook version 5. 
Positive labeling was quantified using ImageJ.  Data were analyzed for statistical 
significance using Student’s t-test (SigmaPlot 11). 
 
III.  Results 
The effect of KU-32 treatment on abnormal Tau in the JNPL3 transgenic mice 
We first tested to see if KU-32 could protect the brain against consequences of 
the P301L mutation in the JNPL3 mouse model of Tau pathology.  We determined if 
KU-32 decreased levels of hyperphosphorylated Tau following six months of treatment 
in the JNPL3 mice.  For these studies, we used two different phospho-Tau antibodies, 
AT8 and CP13.  AT8 recognizes phosphorylated S202 and T205, while CP13 
recognizes phosphorylated S202.  Phosphorylation at these sites has been used in 
order to determine the stages of AD progression (Braak et al., 2006).  Also, these areas 
of Tau phosphorylation are considered essential sites that switch Tau function to the 
pathological phenotype observed in AD brain (Biernat et al., 1992).  Phospho-Tau 
labeling was performed on coronal sections from JNPL3 mice chronically treated with 
20 mg/kg of KU-32 and 12.5% Captisol®.  These mice expressed the human P301L 
Tau mutation under the mouse prion promoter that drove expression primarily in the 
frontal cortex and spinal cord. Immunohistochemical labeling revealed that KU-32 
significantly decreased the amount of Tau phosphorylated at S202 as observed in the 
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CP13-labeled Tau (Figure 3.1).  These significant decreases in the KU-32-treated mice 
were observed in the premotor cortical region of JNPL3 mice.  
 
Figure 3.1: CP13-labeled phospho-Tau in the premotor cortex of KU-32 treated 
JNPL3 mice.  (A) Representative examples of brain sections labeled with CP13 
antibodies.  Black arrows indicate positive CP13 labeling.  (B) Quantitative data from the 
densitometric analysis was determined using the number of pixels labeled per square 
micron. (n=7 P301L mice and n=6 P301L + KU-32 mice).  Statistical evaluation of 
significance of differences was carried out using Student’s t test. 
 
A similar decrease in labeling by the AT8 antibodies that react with phosphorylated Tau 
at S202/T205 was observed in the premotor cortex of KU-32-treated JNPL3 mice 
(Figure 3.2).   
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Figure 3.2: AT8-labeled phospho-Tau in the premotor cortex of KU-32 treated 
JNPL3 mice.  (A) Representative examples of brain sections labeled with AT8 
antibodies.  Black arrows indicate positive AT8 labeling.  (B) Quantitative data from the 
densitometric analysis was determined using the number of pixels labeled per square 
micron.  (n=7 P301L mice and n=6 P301L + KU-32 mice).  Statistical evaluation of 
significance of differences was carried out using Student’s t test. 
 
The effect of KU-32 on CP13-labeled Tau rTg4510 mice 
Since we observed significant decreases in hyperphosphorylated Tau in JNPL3 
mice, we assessed whether KU-32 could decrease phospho-Tau levels in a more robust 
mouse model of P301L Tau pathology that also exhibits neurodegeneration, the 
rTg4510 mice.  These mice expressed mutant Tau at a level 17 times higher than that in 
wild type mice.  This genetic mutation was under the CamKIIa promoter that was driving 
expression in the frontal cortex and the hippocampus (SantaCruz et al., 2005).  
Immunofluorescent labeling of brain sections was performed using CP13 antibodies that 
recognize phosphorylated S202 on Tau.  Images from KU-32 and vehicle-treated 
P301L P301L + KU32
P
ix
e
l 
d
e
n
s
it
y
 o
f 
la
b
e
le
d
 c
e
ll
s
(p
e
r 
s
q
u
a
re
d
 µ
m
)
0
500
1000
1500
2000
2500
3000
# p< 0.05 
KU32 + P301L 
n=6 
P301L 
n=7 
AT8 
AT8 
P
ix
e
l 
d
e
n
s
it
y
 o
f 
la
b
e
le
d
 c
e
ll
s
 
(p
e
r 
!
m
2
) 
B 
A 
 
 113 
rTg4510 mice showed a significant decrease in CP13-labeled Tau in the premotor 
portion of the frontal cortex (Figure 3.3). 
 
Figure 3.3: Chronic administration of KU-32 on CP13-labeled Tau in rTg4510 mice. 
(A) Representative examples of brain sections labeled with CP13 antibodies.  (B) 
Quantitative data from densitometric analysis was based on the number of pixels 
labeled per square micron.  (n=8 KU-32-treated mice and n=8 CAP-treated mice).  
Statistical evaluation of significance of differences was carried out using Student’s t test. 
 
The effect of KU-32 on neuroprotection in rTg4510 mice 
The rTg4510 mice show severe neurodegeneration and synaptic pathology 
beginning at about 2.5 months of age (Spires et al., 2006).  Therefore, we evaluated 
several indicators of neuronal and synaptic integrity and viability in the rTg4510 mice 
treated with KU-32 or Captisol® only as described in Methods.  First, we performed 
immunofluorescent labeling to determine if KU-32 provides protection against 
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development of dystrophic neurites typically associated with mutant Tau 
overexpression.  Sections from the wild type, KU-32, and 5% Captisol®-treated 
transgenic mouse brains were labeled with the dendritic marker MAP2.  Images were 
captured from the premotor cortex (Figure 3.4A) and the CA1 of the hippocampus 
(Figure 3.4B) demonstrated that in transgenic mice treated with KU-32 there was 
improved dendritic morphology when compared with the dendritic field in 5% Captisol®-
treated rTg4510 mice.  Morphometric analyses of dendritic labeling from the 
hippocampal CA1 and the premotor cortex indicated that KU-32-treatment significantly 
increased positive labeling and the integrity of dendrites in comparison to when similar 
sections were analyzed in the Captisol®-treated mice (Figure 3.5).  Dendritic labeling in 
the premotor cortex of the KU-32-treated mouse brains was not significantly different 
from the wild type indicating that KU-32 preserved dendritic structures and resulted in 
nearly normal fields in the treated mouse (Figure 3.5).  In the hippocampal CA1 region, 
the dendritic labeling in the KU-32-treated brains was statistically higher than the 
Captisol®-treated mice.  The MAP2 labeling in the treated mice did not reach the levels 
of that in the wild type mice.  Given that the wild type mice have no lesions due to 
mutant Tau expression, one would expect that there is a basic difference between the 
treated-transgenic mice and the wild-type mice. 
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Figure 3.4:  MAP2 labeling in the premotor cortex and CA1 of rTg4510 mice.  (A) 
Representative examples of brain sections from the premotor cortex were labeled with 
MAP2 antibodies.  (B) Representative images of brain sections from the CA1 of the 
hippocampus labeled with MAP2 antibodies.  White arrows indicate positive MAP2 
labeling. (n=8 KU-32-treated, n=8 CAP-treated, and n=4 WT mice)  
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Figure 3.5: Densitometric analysis of MAP2 labeling in rTg4510 mice. Quantitative 
data from the (A) premotor cortex and (B) CA1 of the hippocampus were determined 
using the number of pixels labeled per square micron. (n=8 for KU-32-treated, n=8 for 
CAP-treated, and n=4 for WT mice).  Statistical evaluation of significance of differences 
was carried out using Student’s t test. 
   
Another marker we evaluated for in vivo neuroprotection with KU-32 in the 
rTg4510 mice was synaptic density. Synaptophysin, which labels synaptic vesicles 
present in nerve terminals, showed statistically significant protection against damage in 
the KU-32-treated rTg4510 mice in comparison to the vehicle-treated rTg4510 mice 
(Figure 3.7).  This protection was observed in both the premotor cortex (Figure 3.6A) 
and the CA1 of the hippocampus (Figure 3.6B).  Significant differences were not 
observed when we compared labeling between the KU-32-treated and the wild-type 
mice in either the premotor cortex or the hippocampal regions implying that KU-32 was 
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able to preserve synaptic density to near normal levels in both brain regions.  Although 
there appears to be a difference between the KU-32-treated and wild type mice (Figure 
3.7), the variability in the wild-type mice is quite high which may have contributed to the 
lack of statistical significance. 
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Figure 3.6: Synaptophysin labeling in the premotor cortex and CA1 regions of 
rTg4510 mice.  Representative images labeled with synaptophysin from the (A) 
premotor cortex and (B) CA1 of the hippocampus.  White arrows indicate positive 
synaptophysin labeling. (n=8 KU-32-treated, n=8 CAP-treated, n=4 WT mice). 
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Figure 3.7: Densitometric analysis of synaptophysin labeling in rTg4510 mice. 
Quantitative data from the (A) premotor cortex and (B) CA1 of the hippocampus were 
determined using the number of pixels labeled per square micron. (n=8 KU-32-treated, 
n=8 CAP-treated, and n=4 WT mice).  Statistical evaluation of significance of 
differences was carried out using Student’s t test. 
 
 A third aspect we assessed for neuroprotection was the neuronal marker, NeuN.   
The NeuN antibodies label cell bodies of living neurons and are used as a measure of 
neurodegeneration, i.e., neuronal cell death.  Our results showed that KU-32-treatment 
significantly protected neurons against degeneration in comparison to vehicle treatment 
in the premotor cortex (Figure 3.8A) and the hippocampal CA1 (Figure 3.8B) of rTg4510 
mice.  Morphometric analyses of these images indicate that the protection with KU-32 
was significant in both the premotor cortex and the CA1 of the hippocampus (Figure 
3.9).  NeuN labeling in the frontal cortex of the KU-32-treated mice differed significantly 
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between wild type and KU-32-treated mice, but the labeling between these two sets of 
mice in the hippocampus was not significant, suggesting marked prevention of neuronal 
death with the treatment.  
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Figure 3.8: NeuN labeling in the premotor cortex and CA1 regions of rTg4510 
mice. Representative images labeled with NeuN from the (A) premotor cortex and (B) 
CA1 of the hippocampus.  White arrows indicate positive NeuN labeling. (n=6 KU-
32=treated, n=6 CAP-treated, and n=4 WT mice). 
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Figure 3.9: Densitometric analysis of NeuN labeling in rTg4510 mice. Quantitative 
data from the (A) premotor cortex and (B) CA1 of the hippocampus were determined 
using the number of pixels labeled per square micron. (n=6 KU-32-treated, n=6 CAP-
treated, and n=4 WT mice).  Statistical evaluation of significance of differences was 
carried out using Student’s t test. 
 
IV.  Discussion 
As shown in previous studies, analogs of novobiocin, a C-terminal Hsp90 
inhibitor protect against Aβ-induced cell death in cellular models (Ansar et al., 2007, Lu 
et al., 2008).  In the present study, we used in vivo models of AD to evaluate the 
neuroprotective efficacy of KU-32.  We showed significant decreases in Tau pathology 
in two mutant Tau mouse models as well as neuroprotection against dendritic damage, 
preservation of synaptic density, and decreased cell death.  Our in vivo neuroprotective 
results are similar to previously published results with KU-32 demonstrating motor 
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neuron protection in a mouse model of diabetic peripheral neuropathy (Urban et al., 
2010).  
First we investigated the effect of KU-32 on hyperphosphorylated Tau in two 
mouse models expressing human P301L Tau.  The less robust Tau pathology model, 
JNPL3, demonstrated significant decreases in both CP13 (Figure 3.1) and AT8 (Figure 
3.2)-labeled Tau in the premotor cortex of KU-32 treated mouse brains.  The more 
robust Tau pathology model, rTg4510, exhibited statistically significant decreases in 
CP13 (Figure 3.3) labeled-Tau in the premotor cortex.  Thus, the KU-32 treatment 
decreaseed Tau pathology in mouse models expressing low and high levels of 
abnormal Tau.   
Prior publications support our observations of decreases in hyperphosphorylated 
Tau through treatment with inhibitors of Hsp90.  Greengard’s group used the JNPL3 
mouse model to show lowered levels of abnormally phosphorylated Tau with 
administration of a the N-terminal Hsp90 inhibitor, GA (Dou et al., 2003).  Dickey and 
colleagues also demonstrated decreases in hyperphosphorylated Tau in the JNPL3 
mouse model using a novel N-terminal Hsp90 inhibitor, EC-102 (Dickey et al., 2006).  
As a whole, our results regarding KU-32 mediated in vivo decreases in abnormal Tau 
support previously reported findings. 
 Our results with the rTg4510 mouse model have shown that the presence of 
mutant P301L Tau in mouse brain leads to neurodegeneration (Figure 3.8), synaptic 
loss (Figure 3.6), and neuritic dystrophy (Figure 3.4). The literature contains many 
accounts of synaptic loss associated with AD (Scheff et al., 2006, Knight and 
Verkhratsky, 2010), and our results suggest that chronic treatment with KU-32 has the 
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potential to help preserve normal synaptic density in the premotor cortex and 
hippocampal CA1 (Figure 3.5).  There are also previous reports linking AD with dendritic 
damage (Grace et al., 2002, Jin et al., 2011).  We show significant dendritic damage in 
the premotor cortex and CA1 of the hippocampus in vehicle-treated mice that was 
significantly reduced with chronic KU-32 treatment (Figure 3.7).  Neurodegeneration has 
also been described as a major morphological characteristic in the brain of the rTg4510 
mouse model of AD (SantaCruz et al., 2005, Spires et al., 2006).  Using NeuN as an 
index of neuronal cell survival, we observed much higher neuronal cell survival levels in 
the premotor cortex and hippocampal CA1 regions of the rTg4510 mice following KU-32 
treatment (Figure 3.9).  It should be noted that the images from NeuN labeling in the 
CA1 of the hippocampus (Figure 3.8B) was more diffuse than what was documented in 
the NeuN images from the premotor cortex (Figure 3.8A).  This difference can be 
attributed to the fact that the NeuN antibody recognizes a specific nuclear protein called 
Fox-3 as well as a non-nuclear protein called synapsin I (Kim et al., 2009).  The 
synapsin I protein is highly concentrated in areas of the hippocampus, while lower levels 
of the protein are found in the premotor cortex (Melloni et al., 1993).  Therefore, the 
more diffuse anti-NeuN labeling of the hippocampus may be due to the recognition of 
the more hippocampal specific protein, synapsin I, found in the cell body of neurons. 
 Overall, the results from these experiments strongly support the in vivo efficacy 
of KU-32.  These data warrant further investigations into the activity of KU-32 as a 
potential treatment of AD. 
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CHAPTER FOUR: Exploration of Potential Mechanisms Underlying the 
Actions of KU-32 In Vitro and In Vivo 
 
I.  Introduction 
 Most neurodegenerative disorders are characterized by the presence of protein 
aggregates.  The most common neurodegenerative disease, Alzheimer’s disease (AD) 
has two hallmark protein aggregates.  One of the characteristic protein aggregates is 
the senile plaques, which are made-up of oligomers of the β-amyloid peptide, and the 
second is the neurofibrillary tangles (NFTs) comprised of hyperphosphorylated and 
fibrillar Tau protein.  Designing therapeutics to remove these aggregated proteins 
seems quite likely to be helpful in AD, as there are no disease-modifying agents 
currently available to stop progression of the pathological process. 
  The development of the characteristic aggregates leading to AD is multi-faceted; 
however, the deposition of protein aggregates in the cell leads to an overall decrease in 
cellular function.  Therefore, it seems reasonable to expect that designing therapeutics 
that enhance the protein quality control machinery of the cell would help to improve 
cellular function.  One way to influence the cellular machinery that controls protein 
quality is through the modulation of the Hsp90 protein, a major regulator of the heat 
shock response (Muchowski, 2002, Muchowski and Wacker, 2005, Luo et al., 2008).  
 Previous reports regarding the testing of Hsp90 inhibitors designed to block the 
N-terminal ATPase activity of the protein have shown promising decreases in the Tau 
pathology associated with AD. Greengard and colleagues demonstrated that the N-
terminal ATPase inhibitor, GA, decreased insoluble Tau in an in vitro model of AD, and 
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GA also decreased the levels of hyperphosphorylated Tau induced by okadaic acid 
(OA), a protein phosphatase 2A inhibitor (Dou et al., 2003).  Later, this group of 
scientists performed in vivo studies using GA to demonstrate decreases in 
hyperphosphorylated Tau in cellular and animal models expressing mutant P301L Tau 
(Luo et al., 2007).  Other researchers also demonstrated decreases in 
hyperphosphorylated Tau using novel derivatives of N-terminal ATPase Hsp90 
inhibitors such as EC102 (Dickey et al., 2006, Dickey et al., 2007).  Modulators of the C-
terminal portion of Hsp90 also led to decreases in hyperphosphorylated Tau in vivo in 
mouse models expressing P301L mutant Tau (Chapter 3; unpublished results).  Since 
these C-terminal modulators demonstrate promising therapeutic potential, it is important 
to try to understand the mechanism underlying their beneficial effects.   
 One potential mechanism for decreases in hyperphosphorylated Tau could be 
due to effects of the compound on the activity of kinases involved in Tau fibrillization 
that are also client proteins of Hsp90.  One well-known kinase that has been associated 
with aberrant phosphorylation of Tau in AD is cyclin-dependent kinase-5 (cdk5) (Iqbal et 
al., 2005).  The activity of cdk5 is dependent upon a small membrane-bound fragment 
called p35 (Takahashi et al., 2005).  Previous reports by Greengard and colleagues 
demonstrated that a novel N-terminal Hsp90 ATPase inhibitor, PU24FCl, led to dose-
dependent decreases in p35 with simultaneous decreases in cdk5 activity.  These 
results suggest that N-terminal Hsp90 inhibition allows for p35 degradation by the 
proteasome (Dou et al., 2003).  Since we have previously shown in vivo decreases of 
hyperphosphorylated Tau with KU-32 administration (Chapter 3), it is possible that KU-
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32 could decrease p35 levels and cdk5 activity similarly to the N-terminal Hsp90 
inhibitor used in Greengard’s studies.   
A second potential mechanism elicited upon KU-32 administration is heat shock 
protein stimulation.  Groups using the N-terminal ATPase inhibitors, such as GA, 
suggest that the heat shock response is stimulated upon administration of these 
inhibitors (Sittler et al., 2001).  The proposed mechanism is that inhibition of Hsp90 
releases the transcription factor, HSF-1, that is normally bound to Hsp90 in a multi-
component complex of proteins in the cytosol.  Once HSF-1 is released, it becomes 
phosphorylated, trimerizes, and translocates to the nucleus where it binds to the heat 
shock element present in DNA encoding other chaperones.  HSF-1 binding to these 
heat shock elements leads to up-regulation in transcription of several other heat shock 
proteins such as Hsp70, Hsp40 and Hsp27 (Bagatell et al., 2000).  Research groups 
using N-terminal ATPase Hsp90 inhibitors demonstrated increases in Hsp70, Hsp40, 
and Hsp27, which suggests that these compounds do indeed stimulate the heat shock 
response (Dou et al., 2003, Dickey et al., 2006, Dickey et al., 2007, Luo et al., 2007). 
 Stimulation of the heat shock response also leads to increases in proteins that 
help regulate the function of HSPs that are regarded as co-chaperones, including the 
Bcl-2 associated athanogene (BAG) family.  This family consists of 6 different members, 
4 of which have been shown to associate with Hsp70 (Takayama and Reed, 2001).  
BAG proteins can induce the release of a bound substrate from Hsp70 by mediating 
nucleotide exchange allowing for more substrate-Hsp70 interactions (Sonderman et al., 
2001).   
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 One BAG family member, BAG1, interacts with Hsp70 and Tau (Luders et al., 
2000).  BAG1 contains an ubiquitin-like domain, and is correlated with ubiquitin-
dependent degradation of Tau (Demand et al., 2001).  BAG1 and the ubiquitin-ligase, 
carboxy terminus of Hsc70-binding protein (CHIP), simultaneously bind to Hsp70 to 
ubiquitinate client proteins and target them for degradation (Hartl and Hayer-Hartl, 2002, 
Gamerdinger et al., 2011).  
 Another member of the BAG family, BAG2, has been reported to play a critical 
role in mediating a highly efficient mode of Tau degradation through ubiquitin-
independent mechanisms.  It has been demonstrated that the BAG2/Hsp70 complex 
can tether hyperphosphorylated Tau to the proteasome for degradation without the 
ubiquitination of Tau (Carrettiero et al., 2009).  Lukiw and colleagues have shown that 
expression of BAG2 is inhibited by miR-128, a microRNA that is up-regulated in 
Alzheimer’s disease (Lukiw, 2007), thereby preventing BAG2-associated removal of 
aggregated Tau. 
 We have tested analogs of novobiocin, an inhibitor or modulator of the C-terminal 
portion of Hsp90, in order to assess their potential as a therapeutic for 
neurodegenerative diseases.  As these are novel compounds, it was important to 
investigate the mechanism(s) through which these compounds produce neuroprotective 
effects.  Our hypothesis was that C-terminal Hsp90 modulators essentially act through 
the same mechanism as N-terminal inhibitors.  Therefore, using previous reports of the 
N-terminal Hsp90 inhibitors, we examined the effects of the C-terminal modulators on 
the same protein pathways involved in the established heat shock response.   
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Our studies focused on determining if the inhibition of the C-terminal nucleotide-
binding site in Hsp90 transcriptionally regulated other molecular chaperones and co-
chaperones, and if C-terminal inhibition of Hsp90 activated the same signaling pathway 
as the N-terminal ATPase inhibitors.  We examined two potential mechanisms.  First, 
we looked to see if KU-32 decreased p35 levels and cdk5 activity, which could be 
responsible for the decreases of hyperphosphorylated Tau observed in vivo (Chapter 3).  
Second, we looked at the effects of KU-32 on the heat shock response by investigating 
levels of: Hsp70; BAG1 and BAG2, co-chaperones of Hsp70; and HSF-1.  We 
hypothesized that KU-32 would decrease kinase activity associated with AD while also 
stimulating the heat shock response thereby enhancing the refolding or ubiquitination 
and proteasomal degradation of misfolded Tau. 
 
II.  Materials and Methods 
Preparation of primary neuronal cultures 
 Primary cortical neurons were prepared from day 18 embryonic rat fetuses 
(Harlan Sprague Dawley) as described previously in Chapter 2 of this dissertation 
(Michaelis et al., 1994, Michaelis et al., 1998, Michaelis et al., 2005).  All animal 
procedures were approved by IACUC.  
 
Aβ peptide preparation and cell culture treatments 
 The Aβ25-35 peptide was purchased from Anaspec (Fremont, CA) and prepared 
as previously described in Chapter 2 of this dissertation.  
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 Primary neurons were allowed to grow for 7 days in vitro (DIV7) before any 
treatments.  In order to assess Hsp70 and p35 levels, the cells were treated with 0.01% 
DMSO (vehicle), 5 nM, 50 nM, 100 nM, and 10 µM concentrations of KU-32 for 24 
hours.  The N-terminal inhibitor, geldanamycin (GA), served as a positive control and 
was administered at 50, 200, and 400 nM concentrations for 24 hours. In a separate 
experiment to examine cdk5 activity, primary cortical neurons were treated with 5% 
Captisol® (vehicle) or 100 nM KU-32.  Two hours later, 25 µM Aβ25-35 or 30 µM 
Roscovitine, a cdk5 inhibitor, were added for 48 hours.  The activity of cdk5 was 
measured by using chemiluminescence.  
 
Chemiluminescence method to determine in vitro kinase activity  
Forty-eight hours after initiation of exposure to Aβ25-35, the cells were lysed using 
kinase lysis buffer containing 20 mM Tris-HCl pH, 7.4, 140 mM NaCl, 1 mM PMSF, 1 
mM sodium orthovanadate, 10 mM NaF, 0.1% Nonidet-40, 1 mM EDTA, 26 µM N-[N-
(N-Acetyl-L-leucyl)-L-leucyl]-L-norleucine (ALLN, a Calpain inhibitor), protease inhibitors 
cocktail set III (Calbiochem), and phosphatase inhibitors cocktail III (Sigma).   Following 
homogenization, cellular debris was removed by centrifuging the samples at 10,000 g 
for 10 minutes at 4°C, and the protein concentrations of the supernatant were 
determined using the BCA assay.  Two hundred micrograms of protein were mixed with 
2 µg of cdk5 antibodies (SantaCruz, Santa Cruz, CA) and the samples incubated 
overnight at 4°C with continuous mixing.  After 24 hours, Protein-A Sepharose beads 
(40 µL in a 50% slurry; Sigma) were added to samples, and immune complexes were 
permitted to form for 2 hours with continuous mixing at 4°C.  The beads were collected 
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using centrifugation at 5,000g for 30 seconds and washed 3 times with kinase lysis 
buffer and 3 times with kinase activity buffer (50 mM Tris-HCl pH 7.4, 80 mM β-
glycerphosphate, 20 mM EGTA, 15 mM MgCl2 and 1 mM dithiothreitol), and finally re-
suspended in 40 µL of kinase activity buffer. Twenty µL of beads were incubated with 
2.5 µM ATP and 1 µg of the substrate Histone (H1) for 30 minutes at 24°C.  The 
luminescent kinase reagent mixture (30 µL) from the KinaseGlo Assay Kit (Promega) 
was added to the samples and allowed to incubate for 10 minutes.  This reagent reacts 
with any remaining ATP in the reaction mixture and emits 1 photon/mol ATP.  A 
luminometer was used to measure luminescence, and ATP consumption was calculated 
by subtracting the luminescence of the sample from that of the ATP in a blank sample 
lacking protein.  The ATP consumed was determined using a standard ATP curve 
concentration from 0 to 10 µM.  cdk5 activity was graphed as pmol ATP consumed per 
µg of protein per minute.  Statistical analysis of data was performed using Student’s t 
test. 
 
Immunoblotting for Hsp70 and p35 levels 
KU-32 and DMSO-treated primary cortical neurons were rinsed twice in 
phosphate buffered saline (PBS), lysed in kinase lysis buffer containing 20 mM Tris-HCl 
(pH 7.4) 140 mM NaCl, 1 mM PMSF, 1 mM sodium orthovanadate, 10 mM NaF, 0.1% 
Nonidet-40, 1 mM EDTA, 26 µM N-[N-(N-Acetyl-L-leucyl)-L-leucyl]-L-norleucine (ALLN, 
a Calpain inhibitor), protease inhibitors cocktail set III (Calbiochem), and phosphatase 
inhibitor cocktail III (Sigma), and collected by scraping the dishes and recovering all the 
contents.  Following homogenization, the protein concentration was determined using 
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the bicinchoninic acid assay (BCA) from Thermo Fisher Scientific.  Reducing sample 
buffer (50mM Tris-HCl at pH 6.8, 6.7% glycerol, 2.7% SDS, 0.05% Bromophenol Blue, 
and 250 mM dithiothreitol) was added to 25 ug aliquots of each tissue sample and the 
proteins were resolved by SDS-PAGE.  The proteins were transferred to polyvinylidene 
fluoride (PVDF) membranes as described previously (Zaidi and Michaelis, 1999).  The 
membrane was probed with Hsp70 antibodies against the inducible isoform, Hsp70.1 
(1:500; Assay Designs, Farmingdale, NY) or p35 antibodies (1:200; SantaCruz 
Biotechnology, Santa Cruz, CA).  Actin (1:1000; SantaCruz Biotechnology, Santa Cruz, 
CA) served as a loading control.  Immunoreactive proteins were detected using the 
chemiluminescence substrate kit (KPL, Gaithersburg, MD).  All primary incubations 
were completed on the same membrane. One Minute Stripping Buffer (GM Biosciences, 
Rockville, MD) was used to remove the previously bound antibodies.  Densitometry was 
performed on the p35-labeled immunoblots.  Experiments were repeated as indicated in 
the figures for verification. 
 
Mouse treatments to assess molecular chaperone levels 
For immunohistochemistry studies, 129S6xFVB mice were treated one time with 
an intra-peritoneal injection of 20 mg/kg of KU-32 or 5% Captisol® (vehicle).  Mice were 
sacrificed with CO2 inhalation at 6 hours, 1 day, 2 days, 3 days, 4 days, 5 days, and 7 
days post injection.  The vehicle-treated mice were sacrificed on day 7 only.  Three 
mice were used per treatment.  Immunohistochemical analysis was performed on the 
mouse brains essentially as described in Chapter 3.   
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In order to assess levels of molecular chaperones with Western blotting and 
qPCR, three-month old FVB mice were treated with 20 mg/kg of KU-32 or 5% Captisol® 
one time.  Three mice per group were sacrificed 96 hours after treatment and prepared 
for protein assessment by immunoblot.   
For analysis of potential trimerization of HSF-1 in response to KU-32 treatment, 
three month old FVB mice were treated with 20 mg/kg of KU-32 or 5% Captisol® one 
time.  The treated and non-treated mice were sacrificed at 6, 12, 24, and 48 hours post-
injection.  For each of the different time points, one mouse each was used for the no 
treatment and Captisol controls, and two mice were sacrificed per KU-32 treatment.  We 
did not find previously published experimental protocols for in vivo analysis of HSF-1 
multimer formation.  Therefore, in order to test for multimer formation, we needed a 
positive control model.  We used primary cortical neurons treated with GA as a positive 
control, while non-treated primary cortical neurons served as a negative control.  The 
GA treated cells lead to HSF-1 trimer formation, while the non-treated cells only have 
the monomeric HSF-1. 
 
Immunohistochemical analysis of 129S6xFVB mice injected with KU-32  
Once the mice were sacrificed, the brains were extracted, cerebella removed, 
and the brains hemisected.  Hemibrains were fixed in 4% paraformaldehyde, 
submerged in 30% sucrose for 7 days, flash frozen in 4-methyl-butane in liquid N2, and 
cut on the cryostat.  Free-floating sections were cut at 20 µm and stored at 4°C in 
1xPBS.  We placed sections in 12-well plates.  The sections were permeabilized with 
0.1% triton-X for 30 minutes, rinsed 2 times in 1xPBS and incubated 30 minutes in 1% 
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hydrogen peroxide in 50% methanol with 0.1% sodium azide to block endogenous 
peroxidase activity.  Slides were rinsed 2 times in 1xPBS and incubated in 2% gelatin 
for 1 hour at 37°C to further block endogenous binding. Using a Vectastain kit, standard 
streptavidin-peroxidase labeling was used with the DAB chromagen (Vector, 
Burlingame, CA).  Primary antibody, Hsp70 (Assay Designs, Farmingdale, NY; 1:500), 
BAG1 (Abcam; 1:500) or BAG2 (Abcam; 1:500) was incubated with the sections 
overnight at 4°C.  Sections were viewed with the Nikon Eclipse 80i microscope and 
images were captured at 40x magnification with the Photometrics CoolSnap camera. 
Positive labeling was quantified using Metamorph.  Experiments were performed in 
triplicate.  Data were analyzed for statistical significance of differences using Student’s t 
test (SigmaPlot 11).    
 
Immunoblotting of brain tissue 96 hours after KU-32 injection in FVB mice 
Mouse brains were extracted, cerebella removed, brains hemisected, and the 
hippocampus was dissected from each half of the remaining brain portions.  One half of 
the remaining brain portion and hippocampal regions were homogenized in a buffer 
containing 0.32 M Sucrose, 0.5 mM MgSO4, 10 mM ACA, 0.1 mM EGTA, 10 mM 
HEPES, 0.1 mM Benzamide, and 0.1 mM Benzamidine (pH 7.4) using a hand-held 
electric homogenizer. The homogenates were centrifuged at 5,000 rpm for 10 minutes 
to obtain crude nuclear and cytosolic fractions. 
After centrifugation, the protein levels of each fraction were determined using the 
bicinchoninic acid assay (BCA) from Thermo Fisher Scientific.  Reducing sample buffer 
(50mM Tris-HCl at pH 6.8, 6.7% glycerol, 2.7% SDS, 0.05% Bromophenol Blue, and 
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250 mM dithiothreitol) was added to 25 µg protein aliquots of each tissue sample and 
the proteins resolved by SDS-PAGE.  The proteins were transferred to polyvinylidene 
fluoride (PVDF) membranes as described previously (Zaidi and Michaelis, 1999).  The 
membrane was probed with Hsp70 (1:500; Assay Designs, Farmingdale, NY), HSF-1 
(1:1000; Assay Designs, Farmingdale, NY) and actin antibodies (1:1000; SantaCruz, 
Santa Cruz, CA).  Actin served as a loading control.  Immunoreactive proteins were 
detected using a chemiluminescence substrate kit (KPL, Gaithersburg, MD).  All primary 
incubations were completed on the same membrane using One Minute Stripping Buffer 
(GM Biosciences, Rockville, MD) to remove the previously reactive antibodies.  
Experiments were completed in triplicate and densitometry was performed. 
 
Quantitative PCR to examine Hsp70 expression 
Mouse brains were extracted, cerebella removed, brains hemisected, and the 
hippocampus was dissected from each half of the remaining brain portions.  One half of 
the remaining brain portion and hippocampal regions were flash frozen in liquid N2, and 
stored at -80°C.  RNA was extracted using the RNeasy mini kit from Qiagen (Valencia, 
CA).  The High Capacity Reverse Transcriptase kit (Applied Biosystems) was used to 
generate cDNA from the tissue extracted RNA.  Nucleic acid concentration was 
estimated with the NanoDrop instrument.  One-hundred nanograms of cDNA from each 
sample was used to measure the amount of Hsp70 and Enolase2 RNA by quantitative 
PCR (qPCR).  The values for Enolase2 were used to standardize the RNA 
measurements for the determination of Hsp70 gene copy number in all samples.  To 
measure Hsp70 expression, the TaqMan Gene Expression Assay kit was used from 
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Applied Biosystems, Mm01159846_s1 Hspa1a (Applied Biosystems, Carlsbad, CA).  
The Enolase2 gene assay kit, Mm00469062_n1 Enolase2, was used to determine 
expression levels of Enolase2 (Applied Biosystems, Carlsbad, CA).  Gene copy 
numbers were calculated based on Hsp70 ratios of KU-32-treated to 5% Captisol-
treated cycle threshold (Ct) values. 
 
Blue native gel electrophoresis of brain samples from KU-32 treated FVB mice 
Blue Native gels are used to assess changes in protein complexes and multimer 
formation (Nijtmans et al., 2002). Brain were prepared as above and sub fractionated by 
centrifugation into three separate fractions: P1, P2, and cytosolic.  Centrifugation was 
performed using a three-spin procedure.  First, the homogenates were spun for 5 
minutes at 3,500 rpm.  The supernatant from this spin was removed, and the pellet was 
re-suspended in homogenization buffer and, spun again for 5 minutes at 3,500 rpm.  
The supernatant was removed, and the pellet from this spin was labeled P1.  The 
supernatants from the first and second spins were combined and centrifuged at 13,000 
rpm for 10 minutes.  The pellet from this spin was P2 and the supernatant was the 
cytosolic fraction.   
Following centrifugation, 2% n-dodecyl β-D-maltoside (DDM) was added to each 
of the P1 and cytosolic fraction samples and each was homogenized using the hand-
held homogenizer.  Samples were centrifuged at 15,500 rpm for 60 minutes.  After 
centrifugation with DDM, the protein levels of each fraction were determined using the 
bicinchoninic acid assay (BCA) from Thermo Fisher Scientific.  NativePage Gel Loading 
Buffer (Invitrogen, Carlsbad, CA) was added to 6 µg protein aliquots of each sample 
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and the proteins were resolved on a NativePage gel (Invitrogen, Carlsbad, CA).  The 
gels were run on ice at 150V for 1 hour using pre-chilled dark blue cathode buffer and 
1X Running anode buffer (both provided by Invitrogen, Carlsbad, CA).  After 1 hour, the 
dark blue cathode buffer was replaced with pre-chilled light blue cathode buffer 
(Invitrogen, Carlsbad, CA) and run at 250V for 3 hours.  After the protein separation, the 
proteins were transferred to polyvinylidene fluoride (PVDF) membranes as described 
previously (Zaidi and Michaelis, 1999).  The membrane was washed in 1% acetic acid 
in 1xPBS solution for 5 minutes before 60 minutes of blocking in 5% non-fat dry milk.  
The membrane was probed with HSF-1 antibodies (1:1000; Assay Designs, 
Farmingdale, NY).  Immunoreactive proteins were detected using the 
chemiluminescence substrate kit (KPL, Gaithersburg, MD).   
   
III. Results 
KU-32 did not significantly alter p35 levels 
Since we have observed decreases in hyperphosphorylated Tau in the brains 
KU-32-treated mouse models expressing mutant Tau (Chapter 3), it was of interest to 
determine if KU-32 treatment might decrease levels of p35. Given that p35 is required 
for cdk5 activity (Kushakawa et al., 2000), and since we observed decreases of the 
phospho-Tau labeling at sites that cdk5 is believed to phosphorylate, we assessed p35 
levels to see if there is a change in p35 levels with KU-32 administration.  Previously, 
Greengard and colleagues demonstrated that N-terminal Hsp90 inhibitors led to a dose-
dependent decrease in p35 levels, which correlated with decreases in cdk5 activity (Luo 
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et al., 2007).  We anticipated that KU-32 would lead to results similar to those published 
by Greengard, and show a dose dependent decrease in p35 levels in primary neurons. 
Primary cortical neurons were treated with KU-32 concentrations ranging from 5 
nM to 10 µM, and DMSO served as the vehicle control.  After 24 hours, the cells were 
lysed and the p35 levels were assessed using Western blots.  We performed these 
experiments 6 times, and determined that there were no changes in p35 levels with KU-
32 treatment (Figure 4.1).  Our positive control, GA, did show dose dependent 
decreases in p35 levels, although those data were not analyzed for densitometric 
values (Figure 4.1). Overall, these studies indicate that KU-32, unlike N-terminal Hsp90 
inhibitors, did not decrease p35 levels.  
 
Figure 4.1: Effect of KU-32 on p35 levels in primary cortical neurons. Primary 
cortical neurons were treated with the vehicle (0.01% DMSO) or indicated doses of KU-
32 and GA.  Twenty-four hours after treatment, cells were lysed, and 25 µg aliquots of 
protein were separated on SDS-PAGE gels.  (A) Representative immunoblot of KU-32 
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treatments on p35 protein levels.  (B) Densitometric analysis of p35 levels using actin as 
the control.  Experiments were repeated 6 times.  (C) Representative immunoblot of GA 
treatment on p35 protein levels.   
 
The activity of cdk5 was not changed with KU-32 treatment 
Although we did not observe changes in p35 levels, it was possible that KU-32 
could affect cdk5 activity without interfering with the interaction between cdk5 and p35.  
Therefore, we pre-treated primary cortical neurons with 100 nM KU-32 for 2 hours, and 
then incubated the cells with 25 µM Aβ25-35 or 30 µM Roscovitine, a cdk5 inhibitor, for 48 
hours.  After the incubation, the cells were lysed, and cdk5 activity was evaluated.  Our 
results showed no effect of KU-32 on the activity of cdk5.  However, this assay 
presented problems that we could not explain.  First, the well-known cdk5 activator, Aβ, 
(Lee et al., 2000) did not significantly increase cdk5 activity in comparison to the non-
treated controls.  Secondly, the potent cdk5 inhibitor, Roscovitine, also did not decrease 
cdk5 activity below control levels in our cultures.  Thus, our failure to demonstrate 
activity under normal control conditions rendered our testing of KU-32 effects of cdk5 
activity inconclusive (Figure 4.2).   
 
 146 
 
Figure 4.2: The effect of KU-32 on cdk5 activity in primary cortical neurons. 
Primary cortical neurons were pre-treated with the vehicle (5% Captisol®) or 100 nM 
KU-32 for 2 hours and then treated with 25 µM Aβ25-35 or 30 µM Roscovitine.  Forty-
eight hours after treatment, cells were lysed, and cdk5 activity was examined.  
Experiments were repeated 5 times. 
 
Hsp70 levels in primary cortical neurons treated with KU-32 
A second potential mechanism for the in vivo effects of KU-32 is the stimulation 
of the heat shock response as is observed with N-terminal ATPase inhibitors.  In order 
to determine if KU-32 treatment activates the heat shock response, we first investigated 
whether there were increased levels of molecular chaperones following exposure to KU-
32.  One molecular chaperone that has been clearly demonstrated to increase upon 
Hsp90 inhibition is Hsp70 (Dou et al., 2003, Dickey et al., 2007, Luo et al., 2007).  We 
treated primary cortical neurons with 5 nM, 50 nM, 100 nM, and 10 µM KU-32 dissolved 
in DMSO as well as 50 nM, 200 nM, and 400 nM of the well-known inducer of the heat 
Control Abeta KU32 Abeta + KU32 Roscovitine
C
D
K
5
 A
c
ti
v
it
y
p
m
o
l 
A
T
P
 c
o
n
s
u
m
e
d
/ 
u
g
 p
ro
te
in
/ 
m
in
0
2
4
6
8
10
12
14
16
18
!!!!!!!!!"#$%#&'()*!
)+,!
 
 147 
shock response, the N-terminal Hsp90 ATPase inhibitor, geldanamycin (GA).  The cells 
were lysed 24 hours post-treatment, and the proteins were separated using SDS-PAGE.  
The Hsp70 labeled immunoblot revealed that protein levels did not increase with KU-32 
administration, even at micromolar concentrations.  As expected, the positive control, 
GA, robustly increased Hsp70 levels at nanomolar concentrations (Figure 4.3).  These 
data suggest that KU-32 does not increase Hsp70 levels upon administration, providing 
evidence that KU-32 does not stimulate the classical heat shock response. 
 
 
Figure 4.3: Hsp70 levels are not changed upon KU-32 administration.  No 
treatment, vehicle (0.01% DMSO), KU-32 (concentration as indicated on the blot), and 
GA (concentration as indicated on the blot)-treated primary cortical lysates were 
separated by SDS-PAGE and analyzed for Hsp70 levels.  Actin labeling was also 
performed and served as a loading control.  GA-treated cells were used as the positive 
control.  This is a representative blot from 2 separate experiments.  
 
Expression of Hsp70 mRNA and protein after in vivo treatment with KU-32 
Since we did not observe changes in Hsp70 protein levels in the primary cortical 
neurons treated with KU-32, but observed marked protection in a mouse model 
overexpressing mutant P301L Tau protein, we decided to determine if KU-32 treatment 
increased expression of Hsp70 protein levels in vivo.  In order to assess potential 
transcriptional and translational up-regulation of Hsp70, we treated FVB mice with 20 
mg/kg of KU-32 or 5% Captisol®, and sacrificed the mice 96 hours later.  Once mice 
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were sacrificed, the cerebella were removed, and the brains were cut in half.  One half 
of the brain was used for mRNA analysis, and the other half was used for protein 
analysis.  The hippocampus was also removed from each brain hemisphere and treated 
separately, in order to assess region-specific changes.  Once the mRNA was isolated, 
qPCR was performed to see if KU-32 administration increased transcriptional levels of 
Hsp70.  The results indicated that KU-32 did not increase expression of Hsp70 in the 
hippocampus or the remaining brain tissues 96 hours post KU-32 treatment in 
comparison to vehicle treated tissue (Figure 4.4). 
 
Figure 4.4: Hsp70 mRNA levels do not change with KU-32 treatment.  Mice were 
treated one time with 20 mg/kg KU-32 and 5% Captisol®.  Ninety-six hours post-
treatment RNA from treated mouse brains and hippocampi were analyzed for Hsp70 
expression.  RNA levels were normalized to Enolase2 and graphed as relative mRNA 
expression compared to 5% Captisol®.  Three mice were used per treatment group.  
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Student’s t test demonstrated no statistically significant changes between KU-32 and 
5% Captisol treated tissues. 
 
As we did not detect changes in the mRNA levels of Hsp70, we determined if 
Hsp70 protein levels might be increased as the mRNA levels may have rapidly 
decreased, but the protein might be elevated for a longer time.  Homogenates of the 
hippocampus and remaining brain were centrifuged to separate the cytosolic and 
nuclear fractions.  These fractions were evaluated for levels of Hsp70 protein using 
Western blotting.  Actin was used as a loading control.  As shown in Figure 4.5, the 
Hsp70 levels did not change either in the cytosolic or nuclear fractions from the 
hippocampus or brain homogenates of KU-32-treated mice.  Overall, these results 
indicate that KU-32 does not change expression or protein levels of Hsp70, and that 
KU-32 does not stimulate the heat shock response at 96 hours post treatment. 
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Figure 4.5: Hsp70 protein levels after 96 hours of KU-32 treatment.  Three mice per 
group were treated with 20 mg/kg of KU-32 or 5% Captisol.  (A) Cytosolic and nuclear 
fractions were separated from brain and hippocampal tissue and analyzed by Western 
blotting.  Representative immunoblots of Hsp70 and Actin (the loading control) labeling 
from cytosolic and nuclear fractions of hippocampus and brain tissue.  (B)  
Densitometric analyses of the immunoblots were completed using Actin as the loading 
control, and were graphed as ratio of Hsp70 to Actin labeling.  The black bars represent 
the cytosolic fraction, and the white bars represent the nuclear fraction.  The graph on 
the left is data from hippocampal tissue, and the graph on the right shows results from 
brain tissue. Student’s t tests were performed and demonstrated no statistically 
significant changes in Hsp70 levels. 
 
KU-32 increased Hsp70 labeling in the somatosensory region of the cortex  
Although there were no changes in Hsp70 levels observed at 96 hours post-KU-
32 treatment, we were interested in determining if the changes in protein levels were 
occurring earlier or later than 96 hours.  Therefore, we treated 129S6 mice with an i.p. 
injection of 20 mg/kg KU-32 or 5% Captisol one time, and sacrificed mice at 6 hours, 2 
days, 3 days, 4 days, and 7 days post injection.  Since we did not detect differences in 
protein levels with immunoblotting and qPCR, we examined Hsp70 levels using 
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immunohistochemical techniques.  This experimental procedure would allow us to 
observe changes in Hsp70 protein levels in all areas of the brain.  Quite unexpectedly, 
we observed that KU-32 significantly increased Hsp70 labeling in the somatosensory 
region of the frontal cortex (Figure 4.6A).  Peak Hsp70 levels were achieved by day 2, 
and Hsp70 returned to basal levels by day 3, as demonstrated by the quantitative 
analysis in figure 4.6B. These results indicate that KU-32 can increase Hsp70 levels in 
vivo, and that these increases appear to be region specific. 
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Figure 4.6: Effect of KU-32 treatment on Hsp70 levels in the somatosensory 
cortex.  (A) Representative images from the somatosensory region of Hsp70 labeled 
mouse brains treated intraperitoneally with 20 mg/kg of KU-32 or 5% Captisol® starting 
at 6 hours for up to 7 days.  The red arrow indicates positive Hsp70 labeling.  (B) 
Quantification of three different mice per treatment day were analyzed and graphed.  
Statistical analysis was determined using Student’s t test to compare each of the time 
points to each other.  Statistical significance is indicated on the graph.  * p<0.05 vs. 6 
hour treatment, and  # p=0.04 vs. 7 day vehicle. 
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Protein levels of co-chaperones, BAG1 and BAG2, after KU-32 administration 
Co-chaperone interaction with Hsp70 is important, as this interaction directs the 
outcome of the client protein bound to Hsp70.  The fate of the client protein will depend 
on which co-chaperone is bound to Hsp70 (Kampinga and Craig, 2010).  Since region 
and time specific increases were described with Hsp70 upon KU-32 administration, we 
set out to determine if two well-described Hsp70 co-chaperones, BAG1 or BAG2, were 
changed with KU-32 administration at the same time and in the same region.  129S6 
mice were treated once with an i.p. injection of 20 mg/kg of KU32 or 5% Captisol®.  The 
mice were sacrificed 6 hours, 2 days, 3 days, 4 day, and 7 days post treatment, and the 
brains were prepared for immunohistochemical labeling.  Antibodies against the co-
chaperones, BAG1 and BAG2, were used to determine if KU-32 administration changed 
the protein levels of these Hsp70 binding partners.  The results from the BAG1 labeling 
indicate that KU-32 treated mice trended toward an increase in the protein levels in the 
somatosensory cortex by day 2, and that this was sustained until day 7 (Figure 4.7).  It 
is important to note that these differences were not statistically significant.  BAG2 
labeling results demonstrated increases in the protein by day 2 that was maintained 
until day 4 (Figure 4.8).  These results suggest that as levels of Hsp70 increase, so do 
levels of these co-chaperones, indicating a potential mechanism for neuroprotection. 
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Figure 4.7: BAG1 levels following KU-32 treatment. (A) Representative images from 
the somatosensory region of BAG1 labeled brains from mice treated with 20 mg/kg of 
KU-32 or 5% Captisol® starting at 6 hours for up to 7 days.  The red arrow indicates 
positive BAG1 labeling.  (B) Quantification of three different mice per treatment day 
were analyzed and graphed.  Statistical analysis was completed using Student’s t test to 
compare each of the time points to each other.  No statistical differences were 
observed. 
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Figure 4.8: BAG2 levels in the somatosensory cortex upon KU-32 administration.  
(A) Representative images from the somatosensory region of BAG2 labeled mouse 
brains treated with 20 mg/kg of KU-32 or 5% Captisol® starting at 6 hours for up to 7 
days.  The red arrow indicates positive BAG2 labeling.  (B) Quantification of three 
different mice per treatment day were analyzed and graphed.  Statistical analysis was 
determined using Student’s t test to compare each of the time points to each other.  
Statistical significance is indicated on the graph.  * p<0.027 vs. 6 hour treatment. 
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Effects of KU-32 on HSF-1 levels  
As previously described, when the heat shock response is activated the 
transcription factor HSF-1 is trimerized and translocated to the nucleus where it 
increases transcription of molecular chaperones.  We did not observe any changes in 
Hsp70 levels with immunoblotting techniques; however, it is possible there are 
increases in other molecular chaperones involved in the heat shock response.  As there 
are various molecular chaperones involved in the heat shock response, we were 
interested in assessing activation of the heat shock response by looking for changes in 
the transcriptional factor HSF-1 after administration of KU-32.  FVB mice were treated 
one time with 20 mg/kg of KU-32 or 5% Captisol® and sacrificed 96 hours after 
treatment.  The brains were excised from the mice, the cerebella were removed, and 
the hippocampus was dissected from the remaining brain tissue.  The tissues were 
homogenized and subjected to centrifugation to separate the cytosol from the nuclear 
material.  These fractions were evaluated using Western blotting.  As shown in Figure 
4.9, KU-32 did not change levels or location of HSF-1 in the hippocampal or the 
remaining brain tissue.  There was no detectable KU-32 mediated translocation of HSF-
1 to the nuclei, although HSF-1 was present in the nuclear fraction.  These data further 
suggest that KU-32 is not acting through a mechanism similar to N-terminal Hsp90 
ATPase inhibitors, and does not stimulate translocation of the transcription factor, HSF-
1.  However, it should be noted that we did not check to see if GA mediated 
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translocation of HSF-1.  
 
Figure 4.9: KU-32 effects on HSF-1 levels in the nuclear or cytosolic fraction of 
brain or hippocampal tissue.  Three mice per group were treated with 20 mg/kg of 
KU-32 or 5% Captisol®.  (A) Cytosolic and nuclear fractions were separated from brain 
and hippocampal tissue then analyzed by Western blotting.  Representative 
immunoblots of HSF-1 and Actin (the loading control) labeling from cytosolic and 
nuclear fractions of hippocampus and brain tissue.  (B) Densitometric analyses of the 
immunoblots were completed using Actin as the loading control, and were graphed as 
ratio of HSF-1 to Actin labeling.  The black bars represent the cytosolic fraction, and the 
white bars represent the nuclear fraction.  The graph on the left is data from 
hippocampal tissue, and the graph on the right is results from brain tissue. Student’s t 
tests were performed and demonstrate no statistically significant changes in HSF-1 
levels. 
 
HSF-1 trimerization with KU-32 treatment up to 48 hours 
While changes in the protein levels and location of HSF-1 did not change upon 
KU-32 administration, we set out to determine if KU-32 stimulated detectable 
trimerization of HSF-1. In order to look at trimerization and translocation of HSF-1 
following KU-32 exposure, we treated FVB mice one-time with 20 mg/kg of KU-32 or 5% 
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Captisol®.  Six, 12, 24, and 48 hours post-treatment we sacrificed the mice, extracted 
the brains, and removed the cerebella.  Centrifugation was performed to separate the 
cytosolic and nuclear fractions.   Native Blue gels were used to maintain the intrinsic 
conformation of the protein complexes, and HSF-1 antibodies were used to visualize the 
bands after separation.  These results revealed that KU-32 did not stimulate 
trimerization of HSF-1 up to 48 hours post KU-32 administration.  In its monomeric form, 
HSF-1 is about 85 kDa, and the trimeric form is about 270 kDa.  As to be expected, the 
nuclear fraction demonstrates more HSF-1 trimer formation in comparison to the 
cytosolic HSF-1; however, KU-32 administration does not stimulate an increase in the 
multimeric formation of HSF-1 in the nucleus or the cytosol.  These results suggest that 
KU-32 administration does not increase translocation or trimerization of HSF-1.  
Interestingly, we did not expect to observe trimerization of HSF-1 in the no treatment 
animals, as there was no stimulation applied to the animals to activate the heat shock 
response.  Our controls using no treatment and GA-treated primary cortical lysates 
demonstrate that HSF-1 was not trimerized with no treatment ,but GA robustly 
increased the trimerization of the protein.  As of now, there are no reports available 
investigating in vivo trimerization of HSF-1.  It appears from our studies that there is a 
basal level of HSF-1 trimerization that occurs in vivo, indicating difficulty in studying 
multimer formation of HSF-1 in animal models. 
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Figure 4.10: KU-32 effects on multimer formation of HSF-1.  (A) Mice were given 
one injection of 20 mg/kg of KU-32 or 5% Captisol®.  At 6, 12, 24 and 48 hours 
following the treatment, the mice were sacrificed.  Cytosolic and nuclear fractions from 
each time point were separated by NativePage gel electrophoresis, and analyzed by 
Western blotting with HSF-1 antibodies.  HSF-1 is about 85 kDa as a monomer.  KU-32 
treatment did not increase HSF-1 trimerization above the 5% Captisol® or the no 
treatment condition.  (B) Non-treated and GA treated lysates were separated by 
NativePage and served as the negative and positive controls.  The no treatment 
condition in lysates showed no trimerization, while the positive control, GA, 
demonstrated trimeric HSF-1.    
 
IV.  Discussion 
The studies presented in this chapter were completed to determine if KU-32 was 
acting through a mechanism similar to N-terminal Hsp90 inhibitors.  As mentioned 
earlier, Hsp90 inhibitors directed at the N-terminus lead to dose dependent decreases in 
p35 and cdk5 activity (Dou et al., 2003) as well as stimulate the heat shock response by 
increasing levels of molecular chaperones i.e. Hsp70 (Luo et al., 2007).  Based on 
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these previous reports, we undertook to determine if our novel C-terminal Hsp90 
inhibitor, KU-32, was acting through a mechanism similar to that known for the N-
terminal ATPase Hsp90 inhibitors.   
We first tested primary cortical neurons treated with KU-32 and the well-known 
N-terminal Hsp90 inhibitor, GA.  Using this technique, we wanted to determine if the 
KU-32-mediated decreases in hyperphosphorylated Tau we observed in vivo (Chapter 
3) were accompanied by decreases in the cdk5 regulatory fragment, p35.  It has been 
demonstrated by Greengard and colleagues that an analog of the N-terminal Hsp90 
inhibitor, GA, dose dependently decreased p35 levels and concurrently decreased cdk5 
activity (Dou et al., 2003).  Unlike the results reported by Greengard, our immunoblot 
studies showed that no changes in p35 levels (Figure 4.1).  Although we did not see 
decreases in p35 levels, we attempted to measure cdk5 activity to determine if KU-32 
directly decreased activity of the kinase as this would lead to decreases in 
hyperphosphorylated Tau.  The experimental results obtained from the cdk5 assay 
showed no significant changes in cdk5 activity upon KU-32 administration.  However, 
since the cdk5 inhibitor, Roscovitine, did not decrease the activity we were measuring 
our results cannot directly address the question of the effects of KU-32 administration 
on the activity of this kinase.  Previous work from our lab has demonstrated robust 
increases in cdk5 activity with the addition of Aβ peptides (Seyb et al., 2007).  
Unfortunately, similar results with cdk5 activity were not obtained our recent rat cultures.  
This could be attributed to the differences in experimenters performing the procedure.   
 Although we did not observe changes with cdk5, there are multiple kinases that 
phosphorylate Tau and lead to fibril formation.  Enzymes such as GSK3β 
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phosphorylates many of the similar sites on Tau that cdk5 phosphorylates (Wang et al., 
1998, Anderton et al., 2001).  Therefore, the in vivo decreases in Tau 
hyperphosphorylation may be mediated by GSK3β.  Other kinases like MAPK, MARK, 
or CaMKII could also be responsible for the changes (Pei et al., 2003, Iqbal et al., 
2005).   
On the other hand, the decreases in phospho-Tau could be mediated by 
increased phosphatase activity.  The activities of protein phosphatase 1 and 2A are 
decreased in AD brain and could decrease accumulation of hyperphosphorylated Tau 
(Gong et al., 1995).  Perhaps KU-32 is stimulating the activity of one or more of the 
phosphatases and thereby leading to increased removal of phosphate from Tau. 
  A second pathway we investigated as a potential mechanism for KU-32 effects in 
vivo, was stimulation of the heat shock response.  We used Western blotting to assess 
Hsp70 levels in primary cortical neurons treated with varying concentrations of KU-32 
and the positive control, GA.  A representative immunoblot (Figure 4.3) of the Hsp70 
treatments demonstrated that KU-32 did not increase Hsp70 protein levels even at 
concentrations up to 10 µM, while the positive control GA, robustly increased Hsp70 
levels above those in non-treated cells.  Conversely, previous reports regarding KU-32 
demonstrate dose-dependent increases in Hsp70 levels in cells and sciatic nerve 
(Urban et al., 2010).  However, the Hsp70 protein level assessment results by Urban 
and colleagues were performed in MCF7 cells, while our experiments were performed in 
primary rat cortical neurons.  Overall, these reports may indicate that KU-32 dependent 
increases in Hsp70 are cell-type specific.  
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 Since we did not observe changes of Hsp70 in vitro we set out to determine if 
different phenomena would be observed in vivo.  Therefore, we treated mice with KU-32 
one time for 96 hours and measured mRNA and protein levels of Hsp70.  Our results 
revealed, once again, that KU-32 did not increase Hsp70 mRNA or protein levels up to 
96 hours in mice.   
 As we only looked at one time point for the in vivo assessment of Hsp70 
expression and protein levels, we decided to use immunohistochemistry to look for 
changes in Hsp70 over time as well as to examine whether changes in Hsp70 were 
region-specific.  We administered 20 mg/kg of KU-32 one time, and sacrificed mice at 6 
hours, 2, 3, 4, and 7 days post-injection.  Immunohistochemical results show that Hsp70 
levels were significantly increased on day 2, specifically in the somatosensory cortex of 
the brain.  These results indicate that in the previous experiment, we may have waited 
too long as Hsp70 levels were measured at 96 hours.  The morphometric analyses from 
the 6 hour to 7 day time treatment studies demonstrated Hsp70 levels were increased 
at day 2, and then decreased to levels similar to vehicle by day 4.  The 
immunohistochemical results showed that increases in Hsp70 levels are region specific, 
and these changes in a small region of the brain may have been overshadowed in the 
immunoblots using whole brain homogenates assessing Hsp70 levels 96 hours post 
KU-32 injection.  This region-focused increase of Hsp70 may be more beneficial for AD 
treatment, as individuals with AD develop protein aggregates in specific brain regions 
such as the hippocampus (Selkoe 2001).  Therefore, providing a therapeutic to 
stimulate proper cellular function in areas of the brain that are primarily affected by the 
aggregated proteins, may prove to be a better alternative.  
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 Since the molecular chaperone machinery has many different players, we 
decided to look at changes in co-chaperones of the BAG family that have demonstrated 
promising interactions with Hsp70 and abnormal Tau protein (Takayama et al., 1999, 
Carrettiero et al., 2009).  Immunohistochemical labeling of the somatosensory cortex of 
the KU-32 treated mouse brains demonstrated that BAG2 levels are significantly 
increased by day 3, while BAG1 results revealed no significant changes.  These results 
provide a potential mechanism for how KU-32 is acting in this region of the brain.  As 
BAG2 plays a role in Hsp70 mediated ubiquitin-independent degradation of abnormal 
Tau through the proteasome (Carrettiero et al., 2009), it is possible KU-32 may be 
mediating increases in processes that efficiently remove proteins from the cell through 
degradation.  Further studies examining ubiquitinated and non-ubiquitinated proteins 
and proteasomal activity in this brain region might address how these protein increases 
are improving cellular function. 
 The heat shock response is controlled by the transcription factor, HSF-1 
(Bagatell et al., 2000).  Since we did not observe changes in Hsp70 like those observed 
with N-terminal ATPase Hsp90 inhibitors, we thought that perhaps the protein levels of 
other heat shock proteins were being changed with KU-32 administration.  Instead of 
focusing on all of the potential heat shock proteins that may have increased, we decided 
to look upstream in the pathway at HSF-1.  
 First, we wanted to determine if KU-32 was prompting the translocation of HSF-
1.  The up-regulation of the proteins involved in the heat shock response requires 
binding of HSF-1 to promoter sequences in the nucleus (Cotto et al., 1996).  So one of 
the first steps involved in the heat shock response is translocation of HSF-1.  Using 
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immunoblots of brain samples from mice treated for 96 hours with 20 mg/kg of KU-32 or 
5% Captisol, we looked at levels of HSF-1 in cytosolic and nuclear fractions.  There 
were no indications that HSF-1 was translocated to the nucleus at 96 hours after KU-32 
administration. 
 The second aspect of HSF-1 we wanted to investigate were changes in multimer 
formation of the protein.  Before HSF-1 translocates to the nucleus in the heat shock 
response pathway, it is phosphorylated and trimerizes (Bagatell et al., 2000).  
Therefore, we decided to move further upstream and determine if KU-32 was inducing 
trimerization of HSF-1.  Surprisingly, results demonstrate that brains of mice treated 
with KU-32, 5% Captisol, or no treatment have trimeric HSF-1 present in the nucleus 
and cytosol in the absence of any stimulus.  As expected, the nuclear fraction had more 
prominent HSF-1 bands than the cytosolic fraction; however, we did not expect the non-
treated brain homogenates to have trimerized HSF-1.  Our immunoblot showing the 
controls with non-treated and GA-treated primary cortical lysates show that trimerization 
only occurred with GA treatment and not in the absence of treatment.  To the best of our 
knowledge, most groups do not investigate HSF-1 trimerization in vivo.  Therefore, it is 
possible that there is a basal level of HSF-1 trimerization occurring to maintain 
activation of molecular chaperones that has not yet been published in the literature. 
 Overall, our results demonstrate that KU-32 appears to act through a different 
mechanism than the N-terminal Hsp90 inhibitors such as GA.  We did observe some 
region specific increases in Hsp70 and BAG2 with KU-32 treatment; however, other 
experiments revealed no changes in HSF-1 translocation and trimerization suggesting 
that KU-32 does not activate the heat shock response in the expected way.  We also did 
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not observe changes in the cdk5 regulatory fragment p35 or cdk5 activity upon KU-32 
administration.  Previous reports using KU-32 demonstrate the therapeutic benefit of 
KU-32 in diabetic peripheral neuropathy (Urban et al., 2010) as well as in neuronal 
protection in AD (Chapter 2 of this dissertation; unpublished results).  Even though KU-
32 does not follow the same pathway as the N-terminal Hsp90 inhibitors, there is still 
promise for this drug as a therapeutic target.  Unfortunately, the mechanism of KU-32 
protection is still unknown, and will need further investigation. 
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CHAPTER FIVE: Exploration of Potential Mechanisms of C-terminal 
Hsp90 Modulation using an Unbiased Approach 
 
I.  Introduction 
  The preceding chapters of this dissertation have demonstrated the 
neuroprotective properties of the novel C-terminal Hsp90 modulator, KU32 (Chapters 1 
and 2; unpublished results); however, the mechanisms of KU-32 protection have yet to 
be fully elucidated.  In order to assess what is happening with KU-32 administration, we 
wanted to use an unbiased approach to look at changes in multiple genes.  One way to 
examine potential changes in the 39,000 genes in the mouse genome without prejudice 
is microarray analysis.  
 We treated mice with 20 mg/kg of KU-32 and vehicle (5% Captisol) to determine 
which changes in a multitude of genes upon drug administration.  We discovered 731 
different probe-sets with significant changes. Of the 731 genes that significantly 
changed, 293 probe-sets were up-regulated and 431 genes were down-regulated.  In 
this final chapter, six genes that were significantly changed with KU-32 treatment will be 
discussed in their relation to maintaining the quality of cellular protein machinery.  
These findings may point the way for future studies.   
 
II.  Materials and Methods 
Microarray Analysis using GeneChip 
 Four-month old SVJ129S6 mice were treated intraperitoneally with 20 mg/kg KU-
32 or 5% Captisol®.  Three mice were used per treatment group.  All mice were 
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sacrificed four days following injection.  Upon sacrificing, the hippocampi were removed 
and flash frozen in liquid N2, then placed at -80°C.  RNA was extracted using the 
RNeasy mini kit from Qiagen (Valencia, CA), and nucleic acid concentration was 
estimated with NanoDrop instrument.  Total RNA (1 µg) was used for hybridization onto 
the Affymetrix Mouse Genome 430 2.0 GeneChip (Affymetrix, Santa Clara, CA), which 
contains probes for over 39,000 gene transcripts from the mouse genome.  This 
process was carried out in the University of Kansas Genomics Facility by Dr. Xinkun 
Wang.  The data were analyzed as described in a previous publication by Dr. Wang 
(Wang et al., 2010).  Overall, statistical significance was based on a Bayesian P value ≤ 
0.05, a fold change ≥ 1.3, and a false discovery rate (FDR) ≤ 1%. 
 
III.  Results 
 The microarray results demonstrated that 731 genes were significantly changed, 
exhibiting at least a 1.3-fold change.  Of these significant changes 431 genes were 
down-regulated and 293 were up-regulated.  A scatter plot (Figure 5.1) demonstrates 
the 731 probe-sets that significantly changed. 
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Figure 5.1:  Identification of differentially expressed genes.  The Mouse Genome 
430 2.0 Affymetrix GeneChip was hybridized to RNA extracted from KU-32 and 5% 
Captisol®-treated 129S6 mice.  Results from over 39,000 genes on the GeneChip 
demonstrate that 731 probe-sets were significantly changed (1.3-fold above or below 
5% Captisol®-treated mice).  The grey circles represent genes that did not significantly 
change, and the red circles are genes that significantly changed.   
 
 As a large number of genes were significantly changed with KU-32 
administration, we analyzed the data to select genes primarily involved in cellular 
maintenance.  These genes are outlined in Table 5.1.  It should be noted that some 
genes that were significantly altered with KU-32 treatment are not well understood in 
terms of their gene ontology categories and their functions in cells. Therefore, we 
decided to investigate probe-sets that have been previously published in the literature.  
The genes found in Table 5.1 will be considered in detail in the discussion section.   
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Table 5.1:  Genes involved in cellular maintenance with significant fold changes.  
The various genes selected that have significantly changed with KU-32 administration 
are outlined, as well as their fold change, gene name and protein function. 
 
IV.  Discussion 
Rhoh 
 The hematopoietic-specific Rhoh protein is a Rho GTPase essential in T cell 
development (Dallery et al., 1995).  Rhoh is a member of the RhoE/Rnd3 subfamily.  
Genes Fold Change Title Function 
Rhoh 13-fold down Ras homolog 
gene family, 
member H, 
mRNA 
GTPase 
Dnajc13 1.75-fold down Hsp40 protein Endosomal 
trafficking 
Mtap9 6.43-fold up Microtubule-
associated 
protein 9 
Cell cycle 
maintenance 
Nos1 4.75-fold up Nitric oxide 
synthase 1  
Synthesizes nitric 
oxide from L-
arginine 
Hdac10 2.00-fold up Histone 
deacetylase 10 
Deacetylates 
lysine residues 
on histones 
Stub1 1.61-fold up Carboxy 
terminus of  
Hsc70 
interacting 
protein 
E3 ligase and 
mediates 
degradation 
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Members of this family remain in the constitutively active GTP-bound state and have no 
intrinsic GTPase activity (Aspenstrom et al., 2007).  Rhoh has demonstrated inhibitory 
capabilities by negatively regulating other Rho GTPases i.e. Rac (Li et al., 2002).  
Overall, RhoH has major implications in the T cell maturation and T cell receptor 
signaling (Gu et al., 2006, Chae et al., 2010).  
     
Dnajc13 
 The Dnajc13 gene codes for a Hsp40, J-domain protein in mammals called 
receptor-mediated endocytosis-8 (RME-8) (Zhang et al., 2001).  RME-8 is broadly 
distributed in tissues with cellular localization on endosomal membranes (Girard et al., 
2005).  This J-domain-containing protein is a major binding partner of the constitutively 
active Hsp70 isoform, Hsc70, and RME-8 assists Hsc70 in endocytosis (Chang et al., 
2004).   
   
Mapt9 
 The Mapt9 gene codes for a microtubule associated protein call Aster-associated 
protein (ASAP) or MAP9 (Saffin et al., 2005).  Mapt9 expression is most prominent in 
areas where microtubules are highly concentrated including the brain, particularly 
growing neurites (Venoux et al., 2008b).  The MAP9 protein plays an essential role in 
the cell cycle, where it localizes to microtubules during interphase to assist mitotic 
spindles during mitosis (Saffin et al., 2005). 
 Interestingly, MAP9 is a substrate of Aurora-A, an oncogenic mitotic kinase.  
When MAP9 is phosphorylated, it is active to assist in mitosis; however, when Aurora-A 
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levels are decreased, MAP9 is targeted for degradation leading to defects in mitotic 
progression.  Therefore, MAP9 is critical for proper mitosis, indicating a potential target 
for cancer therapies (Venoux et al., 2008a).  
 Also, as mentioned previously, MAP9 is highly concentrated in growing neurites.  
Although, neurons of the CNS are post-mitotic, it has been suggested that these cells 
need to have proper cell cycle regulation in order to avoid initiating an altered cell cycle 
state (Herrup and Yang, 2007).  Loss of cell cycle control has been demonstrated in 
several neurodegenerative diseases, including AD (Yang and Herrup, 2007).  Overall, 
these data suggest a potential role for MAP9 in keeping the cell cycle in check, 
particularly in aging neurons.        
 
Nos1 
 The family of enzyme proteins called the nitric oxide synthases (NOSs) is 
responsible for the conversion of L-arginine to citrulline and forming nitric oxide through 
NADH mediated catalysis. It has been suggested that regulation of neuronal NOS 
(nNOS) occurs through Hsp90-based chaperone machinery.  In the presence of an 
Hsp90 inhibitor, there is increased proteasomal degradation of nNOS (Bender et al., 
1999).  Further, it has been demonstrated that the E3 ligase, carboxy-terminus of Hsc70 
interacting protein (CHIP) ubiquitinates nNOS through interactions with Hsp40 and 
Hsp70 (Peng et al., 2004).   
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Hdac10 
 Histone deacetylase-10 (HDAC10) belongs to the Class IIa family of HDACs with 
HDAC6.  The proteins in this class differ from other HDACs in that they have two 
catalytic sites that deacetylate lysine residues on the N-terminal end of core histones 
(Dokmanovic et al., 2007).  HDAC10 and HDAC6 are binding proteins of Hsp90, and 
play pivotal roles in proteasomal degradation of Hsp90 client proteins (Park et al., 
2008).  Recent evidence suggests that decreases in HDAC6 lead to clearance of 
abnormal Tau in a cellular model of AD (Cook et al., 2012).     
 
Stub1 
 Stub1 is the gene that codes for the carboxy terminus of Hsc70-binding protein 
(CHIP).  This protein has a tetratricopeptide repeat (TPR) domain that associates with 
Hsp70 protein (Ballinger et al., 1999) and a U-box domain that has E3, or ubiquitin-
ligase activity.  The E3 enzymes catalyze the third and final step of substrate 
recognition by the proteasome (Hatakeyama et al., 2004).     
As discussed previously in the Introduction of this dissertation, CHIP has been 
implicated in the fate of protein aggregates in AD.  CHIP interacts with Hsp70, Hsp90, 
and Tau, although its most prominent effect is observed through Hsp70 (Grelle et al., 
2006).  CHIP binding to Hsp70 abrogates the ATPase refolding activity of HSP70 
(Ballinger et al., 1999).  CHIP levels are elevated in human Alzheimer’s disease tissue 
(Sahara et al., 2005), suggesting that CHIP plays a part in the formation of Tau tangles.  
This ubiquitin-ligase protein mediates ubiquitination of Tau and increases Tau 
 
 178 
aggregation in AD, where proteasomal degradation is compromised (Petrucelli et al., 
2004). 
Many of the genes that were significantly changed in the microarray analysis 
upon KU-32 administration were unexpected.  The only expected gene that was 
significantly up-regulated with KU-32 treatment was Stub1, or CHIP.  Overall, the results 
from the microarray analysis demonstrate that there are a multitude of genes changing 
with KU-32 administration, leaving many avenues for future investigations.   
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Summary of the Protective Qualities of the Novel C-terminal Hsp90 
Modulator, KU-32 
 
 The chapters in this dissertation have focused on the novel C-terminal Hsp90 
modulator, KU-32.  First, we demonstrated that KU-32 and other novobiocin analogs i.e. 
KU-426, KU-430, and KU-433 are significantly protective against various cellular toxins 
such as Aβ1-42, Aβ25-35, and Thapsigargin (Tg).  KU-32 and KU-430 demonstrated 
similar protection in primary neuronal culture, where these were they only analogs 
tested that protected against Aβ1-42, Aβ25-35, Tg.  When both KU-32 and KU-430 were 
used in the same experiment to test for protection against Aβ peptides, it was 
discovered that KU-32 provided better protection than KU-430.   
 After demonstrating significant protection of KU-32 in primary neuronal cultures, 
we decided to test the effects of KU-32 in vivo.  We treated two AD mouse models 
containing P301L mutant Tau, the JNPL3 and the rTg4510 mice.  In the JNPL3 mice, 
we showed that chronic KU-32 treatment significantly decreased CP-13 and AT8-
labeled Tau in the premotor cortex. The more robust Tau pathology model, the rTg4510 
mice, also demonstrated significant decreases in the CP-13 labeled Tau in the premotor 
cortical region.  As the rTg4510 mouse model also demonstrated neurodegenerative 
qualities in the brain, we assessed the effect of KU-32 on three different markers of 
neuroprotection: synaptophysin for synaptic damage; MAP2 lableling for neuritic 
dystrophy; and NeuN for neuronal loss.  Synaptophysin labeling demonstrated that KU-
32 significantly protected against synaptic damage in the premotor cortex and 
hippocampus.  MAP2 antibody labeling exhibited significant protection of KU-32 against 
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neuritic dystrophy in premotor cortical and hippocampal regions of the brain.  KU-32 
also significantly protected against neuronal loss, as measured by NeuN labeling in the 
premotor cortex and hippocampus.  Overall, KU-32 demonstrated robust protection in 
cellular and animal models of AD. 
 The elucidation of potential mechanisms of KU-32 has been difficult.  We 
demonstrated time and region specific statistically significant increases in the 
somatosensory cortex of Hsp70 and the co-chaperone, BAG2-labeled mouse brain 
sections.  Unfortunately, when using lysate or brain homogenate we did not observe 
changes in Hsp70 or the transcription factor, HSF-1.  These results suggest that in 
order to fully elucidate the mechanism of KU-32 neuroprotection, more experimental 
work needs to be completed. 
 Taken as a whole, the results presented in this dissertation demonstrate that KU-
32 is consistently statistically neuroprotective in cellular and animal models of AD; 
however, the mechanism responsible for this neuroprotection is still unknown.  Since 
this compound exhibits beneficial effects in multiple models, it warrants further 
investigation as a potential therapeutic agent for AD.      
 
 
 
 
 
  
 
